[go: up one dir, main page]

ZA200205879B - Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors. - Google Patents

Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors. Download PDF

Info

Publication number
ZA200205879B
ZA200205879B ZA200205879A ZA200205879A ZA200205879B ZA 200205879 B ZA200205879 B ZA 200205879B ZA 200205879 A ZA200205879 A ZA 200205879A ZA 200205879 A ZA200205879 A ZA 200205879A ZA 200205879 B ZA200205879 B ZA 200205879B
Authority
ZA
South Africa
Prior art keywords
pyrido
pyrimidin
product
found
compound
Prior art date
Application number
ZA200205879A
Inventor
Booth Richard John
Dobrusin Ellen Myra
Josyula Vara Prasad V Nagendra
Mcnamara Dennis Joseph
Toogood Peter Laurence
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA200205879B publication Critical patent/ZA200205879B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Description

PYRIDO[2.3-d]PYRIMIDINE-2.7-DIAMINE KINASE INHIBITORS
FIELD OF THE INVENTION
This invention relates to pyrido[2.3-d]pyrimidine-2.7-diamines that inhibit cyclin-dependent serine/threonine kinases and growth factor-mediated tyrosine 3 kinase enzymes. and as such are useful to treat cell proliferation diseases and disorders.
BACKGROUND OF THE INVENTION Summary of the Related Art
Cell cvcle kinases are naturally occurring enzymes involved in regulation of the cell cvcle (Meijer L.. “Chemical Inhibitors of Cyclin-Dependent Kinases.”
Progress in Cell Cycle Research, 1995:1 :351-363). Typical enzymes include serine/threonine kinases such as the cyclin-dependent kinases (cdks) cdkl, edk2, cdkd4. cdks. cdk6. as well as tyrosine kinases involved in cell cycle regulation.
Increased activity or temporally abnormal activation or regulation of these kinases has been shown to result in development of human tumors and other proliferative disorders. Compounds that inhibit cdks. either by blocking the interaction between a cyclin and its kinase partner. or by binding to and inactivating the kinase. cause inhibition of cell proliferation. and are thus useful for treating tumors or other abnormally proliferating cells.
Several compounds that inhibit cdks have demonstrated preclinical antitumor activity. For example. flavopiridol is a flavonoid that has been shown to be a potent inhibitor of several types of breast and lung cancer cells (Kaur et al., s J Natl. Cancer Inst.. 1992:84:1736-1740: Int. J. Oncol. 1996:9:1143-1168). The compound has been shown to inhibit cdk2 and cdk4. Olomoucine ‘ 25 [2-(hydroxyethylamino)-6-benzylamine-9-methylpurine] is a potent inhibitor of cdk2 and cdk3 (Vesely etal.. Eur. J. Biochem.. 1994:224:771-786). and has been shown to inhibit proliferation of approximately 60 different human tumor cell lines used by the National Cancer Institute (NCI) to screen for new cancer
Ro.
therapies (Abraham et al.. Biology of the Cell. 1995:83:1 05-120). More recently. the purvalanol class of cdk inhibitors has emerged as more potent derivatives of olomoucine (Gray N.S. et al.. Science. 1998:281:533-538). . Tyrosine kinases are essential for the propagation of growth factor signal transduction leading to cell cycle progression. cellular proliferation. differentiation. and migration. Tyrosine kinases include cell surface growth factor receptor tyrosine kinases such as FGFr and PDGF. as well as nonreceptor tyrosine kinases. including c-Src and Ick. Inhibition of these enzymes has been demonstrated to cause antitumor and antiangiogenesis activity (Hamby et al.,
Pharmacol. Ther. 1999:82(2-3):169-193).
Several pvrido[2.3-d]pyrimidines that inhibit cdks and growth factor- mediated kinase enzymes are known (WO 98/33798). US Patent Nos. 5.733.915 and 5.733.914 describe 6-arvl-pyrido[2.3-d]pyrimidines.
Despite the progress that has been made. the search continues for low molecular weight compounds that are orally bioavailable and useful for treating a wide variety of human tumors and other proliferative disorders. including restenosis. angiogenesis. diabetic retinopathy. psoriasis. surgical adhesions, macular degeneration. and atherosclerosis. The present invention provides such compounds. their pharmaceutical formulations. and their use in treating proliferative disorders.
SUMMARY OF THE INVENTION
This invention provides novel pyrido[2.3-d]pyrimidine-2.7-diamine compounds which function as inhibitors of cell cvcle regulatory kinases such as the cvclin dependent kinases as well as the growth factor-mediated tyrosine ] 25 kinases. Thus. these compounds are useful to treat cell proliferative disorders such as atherosclerosis and restenosis: cancer: angiogenesis: viral infections including . DNA viruses such as herpes and RNA viruses such as HIV: fungal infections; type 1 diabetes. diabetic neuropathy and retinopathy: multiple sclerosis: glomerulonephritis: neurodegenerative diseases including Alzheimer’s disease: autoimmune diseases such as psoriasis. rheumatoid arthritis. and lupus: organ transplant rejection and host versus graft disease: gout: polycystic kidney disease: and inflammation including inflammatory bowel disease.
Accordingly, the present invention provides pyrido[2.3-d]pyrimidine 3 having the generic structure of Formula I
RS
A RE
NTO NN
3 | I
A _ 1 ~~ R on N N i
R? RS wherein:
R2.R7. R13, R14 and R153 are independently hydrogen. or lower alkyl, lower alkenyl. or lower alkynyl. each of which is optionally substituted with up to 5 groups independently selected from halogen. cyano. nitro, -R9, -NRIR10. -OR. -(CH2),CO2R?, -(CH2),SO2R 11, -(CH2) R11. -CORY, -CONRIR10, -SO3RY, -S0oNRIR10,-S05RY. -SRY. -PO3RIR10. -PORIRI0, -PONRIR10)5. -NRICOR!10. -NRICO»R 10. -NRICONRIRIO, “NR9S0,R10. or a heterocycle optionally substituted with up to 3 groups independently selected from -R9.-NR9R10 ORY. -NRICOR!10. -COR!0. -(CH1),S0-R! 1. (CHa) RIL or -(CH» R12 optionally substituted with up to 5 groups independently selected from halogen. cyano. nitro. RY, -NROR10. -OR?. -(CH7),CORY. -(CH2),S02R 1. -(CH2) R11. -COR?. .CONRIR10. -SO3R?. -SO>NRIR10, -S0RY. -SRY.
PO3RIR10,-PORIR 10. .PONRIR10);. -NRPCORID,
NR9CO,R10. -NROCONROR 10. .NR9SO-R10. or a heterocycle optionally substituted with up to 5 groups independently selected from -R?. _NROR10. -ORY. _NROCOR!0, -COR10. -(CH2),S0-R! 1. (CH2)nR1!:
R3 is halogen. cyano. nitro. RY. -NRIR10. or -OR®:
R6 is halogen. cyano. nitro. -R9. -NROR10. -OR?. -CO2R?. -COR9, _CONRYRIU. NRYCORI0. -SOaNRIRIU. -50,RY. -SO3R?. -SR”. -PO3R9R10. .PORIR10. -PONRIRIO)5. or lower alkenyl or lower alkynyl optionally substituted with -R:
RS is H. -CO-R13. -COR13. -CONRI3R 14. -CSNRI3RI4. -C(NRI3NRI4RIS, -S03R13.-S0-R13. -S0oNRI3R 14, -.PO3RI3RI4. -POR1I3R14, -PONRI3R14):
RY and R10 are independently hydrogen. or lower alkyl. optionally substituted with up to 3 groups selected from the group consisting of halogen. amino. mono- or dialkylamino, hydroxy. lower alkoxy. phenyl or substituted phenyl, or when taken together with the nitrogen to which they are attached, RY and R10 form a ring having from 3-7 members. up to four of which 0 ’ , ll 20 20 ; may be selected from c. -0O.5.and NR-Y. where R<V is
PN hvdrogen. lower alkyl. or -CO lower alkyl:
R11 is a heteroaryl or a heterocyclic group:
R12 isa cycloalkyl. a heterocyclic. an aryl. or a heteroaryl group: nis0.1.2.0r3: . and the pharmaceutically accepiable salts. esters. amides. and prodrugs thereof.
The present invention also provides a composition that comprises a ’ 25 compound of Formula | together with a pharmaceutically acceptable carrier, diluent. or excipient.
The present invention also provides methods for inhibiting cyclin- dependent kinase and growth factor-mediated kinase enzymes.
The present invention also provides a method of treating subjects suffering from diseases caused by cellular proliferation. The method comprises inhibiting proliferation of tumorigenic cells of epithelial origin and vascular smooth muscle . proliferation. and/or cellular migration by administering a therapeutically effective amount of a compound of Formula I to a subject in need of treatment.
The present invention also provides a method of treating subjects suffering from diseases caused by DNA tumor viruses. such as herpes viruses comprising administering a compound of Formula I.
DETAILED DESCRIPTION OF THE INVENTION
The compounds encompassed by the instant invention are those described by the general Formula I set forth above. and the pharmaceutically acceptable salts. esters. amides. and prodrugs thereof.
In addition to the compounds of Formula I. the invention provides preferred compounds of Formula II: rR 6
NT XN R
7 = = R } EN NT ONT
PN | II 8 ~ R
Rr! 7_1Z Rr! 8
NS
R16 wherein R53. R6. R7. and R8 are as defined above for Formula I: . R16. R17 and R18 are as defined above for the (CHH)pR12 substituents. and preferably are independently hydrogen. halogen. amino. mono- or : dialkvlamino. hydroxy. lower alkyl. lower alkoxy. cyano. nitro. carboxy, carboxvalkyl. aminocarbonyl. mono- or dialkylaminocarbonyl, alkvlcarbonyl. -SO3R9. -SOaNRIR10. -S0-RY. -SRY. -PO3RRID,
_PORIR10. _PONRIR 10). -NRICOR!0. -NRICO,R IV. _NRICONRIR 10. -NR9S0»R 10: or ) R16 is a carbocyclic group containing from 3-7 members. up to 2 of which members are heteroatoms selected from oxygen and nitrogen. wherein the carbocyclic group is unsubstituted or substituted with 1. 2. or 3 groups as defined above. but preferably are independently selected from the group consisting of halogen. hydroxy. lower alkyl. trifluoromethyl. lower alkoxy. amino. mono- or dialkvlamine. aryl. heteroaryl. arylalkyl heteroarvlalkvl. heteroarvlsulfonyl. heteroarvlsulfonylalkyl. heterocyclylalkyl. heterocyclylsulfonyl. or heterocvclvisulfonylalkyl.
Preferred compounds of Formula Il are where R2 is hvdrogen or lower alkyl; RY is hvdrogen. lower alkyl. cyano or halogen: R!7 and R18 are independently hydrogen. halogen. amino. mono- or dialkylamino. hydroxy. lower alkyl. lower alkoxy, aminocarbonyl. mono- or dialkylaminocarbonyl. 13 -SO,NRIR10 or -NRICOR10: and R16 is optionally substituted N-piperidine,
N-piperazine. or N-pyrrolidine. for instance where the ring substituents are selected from -RY. -NRIR10, -OR9. NRICOR10. and COR10.
In addition. the present invention also provides preferred compounds of
Formula III: rR
ML A PR
N N N 11
R? os 0
Ls . wherein R2. RS. and RO are as defined above for Formula I: and
R19 is hydrogen. or lower alkyl. lower alkenyl. or lower alkynyl. each of which is optionally substituted with up to 3 groups independently selected from halogen. amino. mono- or dialkylamino. hydroxy. lower alkoxy. cyano, nitro. carboxy. carboxyalkyl. aminocarbonyl. mono- or dialkylaminocarbonyl, lower alkylcarbonyl. -SO3RY. -S0,NROR 10, -SO-RY. -SRY. -PO3RIR 10. -PORR 10. _PO(NRIR10)5. -NRICOR10. -NRICO-R10. -NRICONRIR10. -NRYSO-R! 0. where RY and R1C are as defined above. or aryl. heteroaryl. arylalkyl. heteroarvlalkyl. cycloalkyl or cvcloalkyi-alkyl. where each aryl. heteroaryl or cycloalkyl group is optionally substituted with up to 5 groups independently selected from halogen. amino. mono- or diatkylamino, hydroxy, lower alkoxy. cvano. nitro. carboxy. carboxyalkyl. aminocarbonyl. mono- or dialkylaminocarbonyl, alkylcarbonyl. -SO3R?, -SO;NRIR10, -$05RY. -SRY. -PO3ROR 10, -PORIR 10. -PONRIR 10). _NROCOR!0, -NROCO,R10, -NRICONRIR!0, -NRISO,RI10, or a (CHp)p-carbocyclic group containing from 3-7 members, up to 2 of which members are heteroatoms selected from oxygen and nitrogen. wherein the carbocyclic group 1s unsubstituted or substituted with 1. 2. or 3 groups independently selected from the group consisting of halogen. hydroxy. lower alkyl. trifluoromethyl. lower alkoxy. amino. mono- or dialkylamino. aryl. heteroaryl, arvlalkyl. heteroarylalkyl. heteroarvisulfonyl. heteroarvisulfonylalkyl. heterocyclylalkyl. heterocyclylsulfonyl, or heterocvclylsulfonylalkyl: and
R21 is hydrogen. lower alkyl. or lower alkyl substituted with phenyl or substituted phenyl.
Preferred compounds of Formula 111 are where RO is hvdrogen or lower ’ alkyl. RY is hvdrogen or halogen. RZ is optionally substituted phenyl: R21 js hydrogen or methyl: and R19 is optionally substituted lower alkyl. cycloalkyl. or (CH»)p-carbocyclic.
An especially preferred group of pyrido[2.3-d]pyrimidines have . Formula IV:
RS
6 21 se ML = _R
HN N N N
IV
AN L=0
RIT gl HN
NS
Rr} 6 wherein R35. R6. R16. R] 7.R18 R19 and R21 are as defined above. Preferred h) compounds of Formula IV are those wherein R21 is hvdrogen or methyl.
Another especially preferred group of invention compounds have
Formula V: rR 6
NT ~ R
M = = rR"!
HN” NT ON NT Vv / \ NJ
NS R16 Hy
RY wherein RS. R6. R16. R17. R18 R19. and RZ! are as defined above. Preferred compounds of Formula V are those wherein R21 is hydrogen or methyl.
The most preferred invention compounds have Formula VI rR : oN NG N-H or alkyl nl A 8 ny 5 7 alkyl or cvcloalkyl
EG
NS
H or alkanoyl wherein R3. R6. R17. and R1 8 are as defined above. and R° and R23 independently are hydrogen or alkyl.
By “alkyl.” “lower alkyl,” and “(C1-Cjq)-alkyl” in the present invention is meant straight or branched chain alkyl groups having 1 to 10 carbon atoms. preferably C-Cg alkyl. Typically alkyl groups include methyl. ethvl. n-propyl, isopropyl. n-butyl. sec-butyl. tert-butyl. pentyl. 2-pentyl. isopentyl. neopentyl, hexyl. 2-hexyl. 3-hexyl. decyl. octyl. and 3-methylpentyl. These groups may be substituted. for instance with halo. C1-C3 alkyl. amino. alkviamino. dialkylamino, hvdroxy. alkoxy. and the like. Examples include chloromethyl. 2-amino-ethyl. and 3-dimethyl-aminopropyl.
By alkenyl.” “lower alkenyl.” and (C»-Cqp)-alkenyl is meant straight or branched chain alkyl groups having 1 to 10 carbon atoms and having 1 or 2 nonadjacent double bonds. Examples of alkenvls include. but are not limited to, 3-butenyl and 1-methyl-3-pentenyl.
By “alkynyl.” “lower alkynyl.” and (Cn-Cg)-alkynyl is meant straight or branched chain alkvl groups having 1 to 10 carbon atoms and having a triple ) bond. Typical alkynyl groups include 2-propynyl and 1.1-dimethyl-3-butynyl.
Substituted alkenyl and alkynyl groups include 4.4-dibromo-2-penteny! and 3-amino-3-hexynyl.
By “alkoxy.” “lower alkoxy.” or ~(C1-Cp)-alkoxy™ in the present invention is meant straight or branched chain alkoxy groups having | to 10 carbon atoms. such as. for example. methoxy. ethoxy. propoxy. ISOPropoxy. n-butoxy,
sec-butoxy. tert-butoxy. pentoxy. 2-pentyl. isopentoxy. neopentoxy. hexoxy. . 2-hexoxy, 3-hexoxy. and 3-methylpentoxy.
The term “alkanovl” means an alkyl group bonded through a carbonyl . moiety. Examples include acetyl and pentanoyl. *Aminoalkanovl” means the alkyl group is substituted with an amino group. Examples include aminoacetyl and 3-aminohexanoyl. “Alkylaminoalkanoy1™ means an aminoalkanoyl group wherein the amine is substituted with a C1-C | alkyl group. and includes methvlaminoacetyl and 4-(isobutylamino)-octanoyl. “Dialkylaminoalkanoyl™ means an N.N-di-substituted aminoalkanoyl group such as diisopropylaminoacetyl.
By halogen in the present invention is meant fluorine. bromine. chlorine, and iodine.
The term “aryl” means an unsubstituted aromatic carbocyclic group having a single ring (e.g., phenyl). multiple rings (e.g.. biphenyl). or multiple condensed rings in which at least one is aromatic (e.g.. 1.2.3.4-tetrahydronaphthyl, naphthyl. anthryl, or phenanthryl). The term “substituted aryl” means an aryl substituted by 1 to 4 substituents selected from alkyl. O-alkyl and S-alkyl. -OH. -SH. -CN, halo, 1.3-dioxolanyl. -CF3, -NO3. -NH2. -NHCH3. -N(CH3)2, -NHCO-alkyl, ~(CH9);COsH. -(CH2)mCOn-alkyl. -(CH2)mSO3H. -NH alkyl, -N(alkyl)s, -(CH7)mPO3Hj. (CHa), PO3(alkyl)2. -(CH2)mSO2NH:. and -(CH2)m SO>NH- alkvl. wherein alkyl is defined as above and m is 0. 1. 2. or 3. Some examples of substituted aryl groups are methylphenyl. isopropoxyphenyl. chlorophenyl. 2-bromo-3-trifluoromethyl-4-nitro-3-aminophenyl. 4-bromobiphenyl, 3- acetamidonaphthyl. 3-dimethylaminoanthryl. 3.4-dimethoxyphenanthryl. and 2,8- dibromobiphenylen-1-yl.
By “heteroaryl” is meant one or more aromatic ring systems of 5-. 6-. or . 7-members containing at least 1 and up to 4 heteroatoms selected from nitrogen, oxygen. or sulfur. Such heteroaryl groups include. for example. thienyl. furanyl, thiazolvl. imidazolyl. (is)oxazolyl. tetrazolyl. pyridyl pvrazinyvl, pyrimidinyl, pyrazolyl, (iso)quinolinyl. napthyridinyl. phthalimidyl. benzimidazotlyl, benzoxazolvl. A “substituted heteroaryl” group can be substituted with 1.2.3. or 4 of the groups mentioned above for “substituted aryl.” such as 2.5.4.6- tetrachloropyridyl and 2-methoxy-3-trifluoromethylthien-4-y1.
The term “heterocyclic group” means a non-aromatic ring having 5-. 6-. or : 7-ring atoms. from 1 to 4 of which are selected from nitrogen. oxvgen. or sulfur. 3 Examples of heterocyclic groups include morpholino. piperidino. piperazino. pyrrolidinyl. and tetrahydrothienyl. Such groups can be substituted with the same groups described above for substituted heteroaryl.
A “carbocyclic group” or “cycloalkyl” is a nonaromatic cyclic ring or fused rings having from 3- to 7-ring carbon members. Exampies include cyclopropyl, cyclobutyl. and cycloheptyl. These rings may be substituted with one or more of the substituent groups mentioned above for aryl, for example alkyl, halo. amino. hydroxy. and alkoxy. Typical substituted carbocyclic groups include 2-chlorocyclopropyl, 2.3-diethoxycyclopentyl. and 2.2.4 4-tetrafluorocyclohexyl.
The carbocyclic group may contain 1 or 2 heteroatoms selected from oxygen, 135 sulfur. and nitrogen. and such ring systems are referred to as “heterocyclyl” or “heterocyclic”. Examples include piperidyl, piperazinyl, pyrrolidinyl, pyranyl, tetrahydrofuranyl, and dioxany!. These heterocyclyl groups may be substituted with up to 4 of the substituent groups mentioned for arvl to give groups such as 3.5-dimethylpiperazin-1-yl. 3.3-diethylpiperazin-1 -yl. 3.3.4. 4-tetramethylpyrrol- idinyl. 3-chloro-2-dioxanyl. and 3.5-dihvdroxymorpholino. These can also bear a keto group. for instance. 3-ketopiperidyl.
The term ~cancer” includes. but is not limited to. the following tumor types: breast. ovary. cervix. prostate. testis. esophagus. glioblastoma. neuroblastoma. stomach. skin. keratoacanthoma. lung. epidermoid carcinoma. large cell carcinoma. adenocarcinoma. bone. colon. adenoma. pancreas. thyroid. follicular carcinoma. undifferentiated carcinoma. papillary carcinoma. seminoma. melanoma. sarcoma. bladder carcinoma. liver carcinoma and biliary passages. kidney carcinoma. myeloid disorders. lymphoid disorders. Hodgkin's. hairy cell carcinoma. cancer of the buccal cavity and pharynx (oral). lip. tongue. mouth, pharynx. small intestine. colon. rectum. large intestine. brain and central nervous svstem: and leukemia.
The compounds of Formulas I to VI can exist as pharmaceutically acceptable salts. esters. amides. and prodrugs. The term “pharmaceutically acceptable salts. esters. amides. and prodrugs” as used herein refers to those carboxylate salts. amino acid addition salts. esters. amides. and prodrugs of the compounds of the present invention which are. within the scope of sound medical ) judgment. suitable for use in contact with the tissues of patients without undue 3 toxicity. irritation. allergic response. and the like. commensurate with a reasonable benefit'risk ratio. and effective for their intended use. as well as the zwitterionic forms. where possible. of the compounds of the invention. The term “salts” refers to the relatively nontoxic. inorganic. and organic acid addition salts and base salts of compounds of the above formulas. These salts can be prepared in situ during the final isolation and purification of the compounds. or by separately reacting the purified compound in its free base form. for example. with a suitable organic or inorganic acid. and isolating the salt thus formed. Representative salts include the hvdrobromide, hydrochloride, sulfate. bisulfate. nitrate. acetate. oxalate, valerate. oleate, palmitate. stearate. laurate. borate. benzoate. lactate. phosphate. tosylate. citrate. maleate. fumarate. succinate. tartrate. naphthylate mesylate. glucoheptonate. lactobionate. and laurylsulphonate salts. and the like. When the compound of the above formulas has one or more acidic groups. it can form a salt by reaction with a base. These salts may include cations based on the alkali and alkaline earth metals. such as sodium. lithium. potassium. calcium. magnesium. and the like. as well as inorganic bases such as ammonium. quaternary ammonium. and other amine cations including. tetramethylammonium. tetraethviammonium. methylamine. dimethvlamine. trimethylamine. triethylamine. ethylamine. and the like. Pharmaceutically acceptable salts are well-known to those skilled in the art of medicinal chemistry. (See. for example,
Berge S.M. et al.. “Pharmaceutical Salts.” J. Pharm. Sci.. 1977:66:1-19 which 1s incorporated herein by reference.)
Examples of pharmaceutically acceptable. nontoxic esters of the ’ compounds of this invention include C1-Cg alkyl esters. wherein the alkyl group is a straight or branched hydrocarbon. substituted or unsubstituted. Esters also include C5-C7 cycloalkyl esters. as well as arvlalkvl esters such as benzyl and triphenvimethyl. C1-Cy Alkyl esters are preferred. such as methyl. ethyl. 2.2 2richloroethvl. and tert-butyl. Esters of the compounds of the present invention may be prepared according to conventional methods. for example by reaction of an acid with an alcohol.
Examples of pharmaceutically acceptable amides of the compounds of this d invention include amides derived from ammonia. primary C1-Cg alkyl amines and secondary C1-Cg dialkyl amines. wherein the alkyl groups are straight or branched. In the case of secondary amines. the amine may also be in the form of a 3- or 6-membered heterocycle containing 1 nitrogen atom. Amides derived from ammonia. C-C3 alkyl primary amines. and C1-C» dialkyl secondary amines are preferred. Amides of the compounds of the invention may be prepared according to conventional methods well-known to the medicinal chemists.
The term “prodrug” refers to compounds that are rapidly transformed in vivo to vield the parent compound of the above formulae. for example, by hvdrolysis in blood or stomach fluids. A thorough discussion of prodrugs is provided by Higuchi T. and Stella V.. “"Pro-drugs as Novel Delivery Systems.” Vol. 14 of the A.C.S. Symposium Series. and in Bioreversible Carriers in Drug
Design. ed. Edward B. Roche. American Pharmaceutical Association and
Pergamon Press. 1987. both of which are hereby incorporated by reference.
Representative compounds of the invention are shown below in Table 1.
Table ~ : nT "NH A SANT A 7 NH 2 no So ~~ EN _ od
Xx ZT XN STN EN PERS ® ol
LJ !
Ng NT
H H H
] 2 3
BY PE = : NF } NE HN ~N N NH HN N » NH
SA BS BY
. = .
FO ra, x
A Cl TS oe (J “
H PN PN
4 5 6
INI PY i oo NTN A SE Ny
AN
HN O PS EN PY
PN HY 0 | HN So
Xn
YG
C _N N =. @ ]
A Bi A 0 A 7 8 9
: Table 1 (cont'd)
NRX NE noo no NTR
TCE i NE mn ONT NT NH i Pi Bl i i ! ‘ HN NT EN “NH
SL Ea l | | = No
NN PN Ng A he cl T GP
N N
O ® S
X X J
11 H 12
NTS INES NE
Pa = Pg = = PN =
HN xT HN ON "NH HN y i NH
HN [@] EN NG
Cl 8 b : § © 13 0 14 © 15
INN NH i NG by EN NG NH = | No = | HN So ~ EN ) - Y { Yeo
Cl a OH N OH _ ~~ § )
N N : : A H 3
O 16 17 18
. Table 1 (cont'd)
E | NRT
NS Vl Ve NRX In A } ) SN TN Nn 7 ray BN a PP 1 + H ‘
HN ONT OY NH NNN PS PS
AS | PN ~ T HN ©
A HNT TO A, HN So LJ B
ER
! N OH
AN OH AN OH dé ™ 9 ) ~~ . re !
N “
H 19 H 20 oP 21
A = = 1 ! A I
HN N x A . Py N= = NH
AN 0 HN [@] NG
Cl - ~ 4 -
N OH , [ ) (0) OH Ne OH h > (
FN A ) 0 ) 22 ¢ 23 07 24
F
JOON SON hd = = | | l Py
HN N N Tr INN H Hn” SNE SN H
A cl | HN 0 gi So = HN 0
AN J NN J
Xn
Cl
N N N
§ h AN AN x LJ or : 25 H 26 H 27
. Table 1 (cont'd)
NTR NTR
, | ! i | i ! ym i AAA
NTN A nS AN RE
To BS I EN
I | | Cl
NY
N ah C) 9 ~~
N N
H 28 oe 29 oA 30
F
UT Sol
TN IAN
SN NH AA NH JOS
PS PS HN” NT ON H
EG XL re Pp = | HN 0)
NS
() a
N Ny oP 31 SE 32 33
N
RENE NH OL REN NT NH
PY Hy NT ONT NH A = = o | " © @ So \ HNO
N @ SS J N -
N
34 35 36 OH
‘ Table 1 (cont'd)
F Aa F
NTR NTT YY NTR
I Ai I
TN NE HN” NC N NH NNN NH
A A
@ HN" YO @ hi @] “J RS ~ ! JN | Pp 37 38 39
F
. - ~~ >
J DG Del IJ
J y ‘ = = HN N N NH
HN N N x HN NN NH JY = y O = HN 0 e Hh = HN 0 9 x
Sy q yi g
OH
40 41 42
NT ~~
Pg = = , NE HN N N NH
PN = oN No = | HN 0 I '
J
N ve NT - h
OH N CH; 43 44 ( )
N
H «3 HCI
F
~~ pe”
HN ONT NT SNH, SN N—CH; 0
NH
A
N rr ANN NG
A
(ot 0
CO. Et
A
Sx NN” >N— CH, CH- AE NT 2X5 NH, c=0
NH
«3 HCI ® )
N
: ) 0+
I
0 ocHy; CH-NH,
NHCCH.-
IY 3 . Soo ~ oo
HY N” "NT NH Sn N7 NH
CH,CH, NH, 70 Cl C=s
CH; NH.
Br - ¢=0
N
“7 N
CHI ep, >)
NO» NO . Sod NF NS P-OCH,
J Jo ML ocn,
HN N° 'N ik HN N° N NH 0 0) To CH; SO,CH, : OCH, _N «TFA ® 3
Representative compounds of the present invention. which are encompassed by Formula I. include. but are not limited to. the compounds in
Table 1 and their pharmaceutically acceptable acid or base addition salts. ester or 3 amide analogs. and prodrugs thereof.
The compounds of the present invention can exist in unsolvated forms as well as solvated forms. including hydrated forms. In general. the solvated forms. including hydrated forms. are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
Some of the compounds of Formula I have one or more chiral centers. and can thus exist as individual stereoisomers and mixtures thereof. Other compounds can exist in more than one geometric form. This invention includes all optical and geometric isomers and forms. and mixtures thereof. Racemic mixtures of invention compounds are readily resolved into individual isomers by routine methods such as chromatography. fractional crystallization. and classical resolution using optically active acids and salts. The individual isomers can also be prepared by chiral synthesis. including chiral hvdrogenations and the like using commercially available chiral catalysts. ) The compounds of the present invention are useful for treating cancer (for example. leukemia. and cancer of the lung. breast. prostate. and skin such as : melanoma) and other proliferative diseases. including. but not limited to, psoriasis. HSV. HIV. restenosis. and atherosclerosis. To utilize a compound of the present invention to treat cancer. a patient having cancer 1s administered a therapeutically effective amount of a pharmaceutically acceptable composition comprising an invention compound.
A further embodiment of this invention is a method of treating patients . suffering from diseases caused by vascular smooth muscle cell proliferation.
Compounds within the scope of the present invention effectively inhibit vascular smooth muscle cell proliferation and migration. The method entails inhibiting vascular smooth muscle proliferation. and or migration by administering an effective amount of a compound of Formulas I to VI to a subject in need of treatment. “Subject” and “patient”. as used herein. 1s a mammal such as a human. but also includes horses. cattle. sheep. and companion animals such as dogs and cats.
The compounds of the present invention can be formulated and administered in a wide variety of oral and parenteral dosage forms. including transdermal and rectal administration. It will be recognized to those skilled in the 135 art that the following dosage forms may comprise as the active component. either a compound of Formula I or a corresponding pharmaceutically acceptable salt or solvate of a compound of Formula I.
A further embodiment of this invention is a pharmaceutical composition comprising a compound of Formulas [ to VI together with a pharmaceutically acceptable carrier. diluent. or excipient therefor. For preparing pharmaceutical compositions with the compounds of the present invention. pharmaceutically acceptable carriers can be either a solid or hquid. Solid form preparations include powders. tablets, pills. capsules. cachets. suppositories. and dispensable granules.
A solid carrier can be one or more substances which may also act as diluents, flavoring agents. binders. preservatives. tablet disintegrating agents. or an encapsulating material.
In powders. the carrier is a finely divided solid such as talc or starch which ) is in a mixture with the finely divided active component. In tablets. the active component is mixed with the carrer having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
The formulations of this invention preferably contain from about 5% to about 70% or more of the active compound. Suitable carriers include magnesium carbonate. magnesium stearate. talc. sugar. lactose. pectin. dextrin. starch. gelatin.
alo tragacanth. methylcellulose. sodium carboxymethylcellulose. a low melting wax. cocoa butter. and the like. A preferred form for oral use are capsules. which include the formulation of the active compound with encapsulating material as a . carrier providing a capsule in which the active component with or without other carriers. is surrounded by a carrier. which is thus in association with it. Similarly. cachets and lozenges are included. Tablets. powders. capsules. pills. cachets. and lozenges can be used as solid dosage forms suitable for oral administration.
For preparing suppositories. a low melting wax. such as a mixture of fatty acid glvcerides or cocoa butter. is first melted. and the active component 1s dispersed homogeneously therein. as by stirring. The molten homogenous mixture is then poured into convenient size molds. allowed to cool. and thereby to solidify.
Liquid form preparations include solutions. suspensions. and emulsions such as water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution. isotonic saline. 5% aqueous glucose. and the like. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants. flavors. stabilizing and thickening agents as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water and mixing with a viscous material. such as natural or synthetic gums. resins. methylcellulose. sodium carboxymethylcellulose. or other well-known suspending agents.
Also included are solid form preparations that are intended to be converted. shortly before use. to liquid form preparations for oral administration.
Such liquid forms include solutions. suspensions. and emulsions. These preparations may contain. in addition to the active component. colorants. flavors, stabilizers. buffers. artificial and natural sweeteners. dispersants. thickeners. solubilizing agents. and the like. Waxes. polvmers. microparticles. and the like can be utilized to prepare sustained-release dosage forms. Also. osmotic pumps can be emploved to deliver the active compound uniformly over a prolonged period.
The pharmaceutical preparations of the invention are preferably in unit dosage form. In such form. the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation. the package containing discrete quantities of preparation. such as packeted tablets. capsules. and powders in vials or ampules.
Also. the unit dosage form can be a capsule. tablet. cachet. or lozenge itself. or it can be the appropriate number of any of these in packaged form. - The therapeutically effective dose of a compound of Formula I will 3 generally be from about 1 to about 100 mg/kg of body weight per day. Typical adult doses will be about 30 to about 800 mg per day. The quanuty of active component in a unit dose preparation may be varied or adjusted from about 0.1 10 about 500 mg. preferably about 0.5 to 100 mg according to the particular application and the potency of the active component. The composition can. if desired. also contain other compatible therapeutic agents. A subject in need of treatment with a compound of Formula I is administered a dosage of about | to about 500 mg per day. either singly or in multiple doses over a 24-hour period.
The compounds of the present invention are capable of binding to and inhibiting the activity of proteins having the ability to phosphorylate other proteins. such as cdks, PDGFr. FGFr. c-Src. and EGFr. Cdks form complexes with cyclins. and these complexes phosphorylate key proteins allowing cells to proceed through the cell cycle (Meijer L., Progress in Cell Cvcle Research, 1995:1:351-363). The compounds of this invention inhibit this phosphorylation and therefore can be used as anti-proliferative agents for the treatment of cancer and/or restenosis and other proliferative diseases.
Because of their inhibitory activity against cdks and other kinases, the compounds of the present invention are also useful research tools for studying the mechanism of action of those kinases. both in vitro and in vivo.
The preparation and use of the compounds of this invention are further described in the following detailed example. The examples are intended to illustrate particular embodiments of the invention. and are not intended to limit the scope of the specification or the claims in any way. The invention compounds are prepared by synthetic methodologies well-known to those skilled in the art of } organic chemistry. and utilize commercially available starting materials and reagents.
It may be desirable during the synthesis of an invention compound to derivatize reactive functional groups in the molecule undergoing reaction so as to avoid unwanted side reactions. Functional groups such as hvdroxy. amino. and acid groups typically are protected with suitable groups that can be readily i removed when desired. Use of common protecting groups is described fully by
Green and Wuts in Protective Groups in Organic Synthesis. J ohn Wiley and Sons. : New York. New York (2™ Edition. 1991). Typical hydroxy protecting groups 3 include ether forming groups such as benzyl. and aryl groups such as tert-butoxvcarbonyl (Boe). formyl. and acetyl. Amino protecting groups include benzyl. anvl such as acetyl. and trialkvisilyvl groups. Carboxyiic acid groups rvpically are protected by conversion to an ester that can be easily hydrolyzed. for example. trichloroethyl. tert-butyl. benzyl. and the like.
As noted above. some of the invention compounds have one or more chiral centers. and thus can exist as individual optical isomers and geometric 1SOmers. and mixtures thereof. Compound 106. for example. has two asymmetric centers, and has the cis configuration. This invention includes all such geometric 1SOmers. enantiomers and RS racemates. as well as the individual R or S isomers of chiral 13 compounds. All individual isomers and mixtures thereof are included in this invention. Individual isomers are readily prepared by a chiral synthesis. or by conventional resolution techniques well-known to those skilled in the art.
An illustration of the preparation of compounds of the present invention is shown in Schemes 1-4. The synthesis of Compound 1 (Example 13) is depicted in
Scheme 1: however. it should be recognized that the general scheme is applicable : 10 all of the invention compounds. Each step shown in the Schemes 1s further illustrated in the detailed examples that follow.
In Scheme 1. a 2-methylthio-4-halo-3-alkoxycarbonylpyrimidine 1s reacted with ammonium hydroxide to give the corresponding 4-amino derivative. The ester is reduced by reaction by reaction with LiAl Hg to give the 5-hvdroxvmethyl analog. which in turn is oxidized to a 3-formy! derivative. The 5-formyl group is converted to an unsaturated (acrviate) group. which is cyclized to form a pyrido[2.3-d]pyrimidine. The pvridopyrimidine is converted to a key intermediate. namely 2-methylsulfanyl-pyrido[2.3-d]pyrimidine-7-ylamine. which 50 is readily oxidized to give a 2-methvlsulfinyl analog. The 2-methylsulfinyl group is easily displaced by reaction with an amine RoNH» to provide the invention
JA compounds of Formula I. The 7-amino group on the pyridopvrimidine ring is } readilv converted to a urea by reaction with an isocyanate such as R19 N=C=0.
Scheme ’ 0 O
TN N TN 1 ~N ] NT 0 a NT 0 b n OH = = : ® N Cl S N NH- S N NH, : - i 0 o i Hi
NN c SN d NG — | —_— [ | —
BENZ SN
RE NTS ¢ 3] XTX
AZ Xg s7NT NT al S NH,
H | -
NTN IANS
TY
— —
INN SN Nk ~~ NS . . h N 1 J ao AL i i NH, (0)
Y
Boc
NT YT NTT
Pe = IN BY = =
HN Y N ° — HN N y H
HN 0 9 EN
S$ @ » . i H 1 . Boc
The reactants shown in Scheme 1 have the following meanings: (a) NH3; (b) LAH: (c) MnO2; (d) Ph3PCHCO»EL: (¢) DBU: (f) POCl3: (g) NH3: (h) (+)-Trans-2-(phenylsulfonyl)-3-phenyloxaziridine: (i) 4-(4-Boc- : piperidine)aniline: (j) NaH. t-Butylisocyanate: (k) HCI
Scheme 2 illustrates an alternative synthesis of pyvridopyrimidine having a urea functionality at the 7-position. Whereas such ureas were prepared in
Scheme 1 by reaction of an isocyanate with a 7-amino-pyridopyrimidine,
Scheme 2 utilizes carbonyvldiimidazole to provide an intermediate imidazolide.
The imidazolide readily reacts with an amine R19NHj to give the corresponding urea. Scheme 2 illustrates this process by showing the synthesis of Compound 51. and is more fully described in Example 32.
Scheme 2
NTO NN NTO
Nz = a MN ~ = b. c
HN ! NH, — | HIN v y \H —
LL Py
AN Ay NT So i | [I {i oN i ~~ oe \—
N
B
Boc oc
NT ~
MN ~ =
HN y I JY
QO HN” 0 ~ 0 q
H 51
Conditions: (a) NaH. Carbonvldiimidazole: (b) Cvclopentylamine: (¢) HCI
Compounds of Formula 1 may also be prepared according to Scheme 3, 3 wherein the synthesis of compound 4 (Example 43) is depicted. 4-Amino-2- methanesulfanyl-pyrimidine-3-carboxaldehyde is reacted with methyl magnesium bromide to give the corresponding 3-(2-hydroxyethyl)-pyrimidine. The alcohol is oxidized to give the methyl ketone analog. The methyl ketone is reacted with diethvl cvanomethy! phosphonate and cyclized to a 3-methyl-7-amino- pyridopvrimidine. Further reaction as in Schemes 1 or 2 gives invention compounds such as compound 4.
Nell
Scheme 3 . 0 A
NT Ho, on 5 NT 0 0 = a = A
S NH, 57 7S NH, STN NH 2 2 2 1
NP as in PE c N TOON Scheme 1 or 2 | A ——— | —_—
AA = = HN 0
S N” SNH, | EN - NN 9
No
Conditions: (a) MeMgBr: (b) MnO»: (¢) (EtO)72P(O)CHHCN
Compounds of Formula 1 may also be prepared according to Scheme 4, 3 wherein the synthesis of compound 12 (Exampie 40) is depicted. In this scheme. the 2-methylthio group of a pyrimidine is first oxidized to the corresponding methvlsulfinyl analog. The methylisulfinyl group 1s displaced by reaction with an amine R2NH>. The 3-carboxaldehvde is then derivatized as in Scheme 1 and cyclized to give the corresponding 2-(R2ZNH) substituted 7-amino pyvridopvrimidine. The 7-amino group is arylated or otherwise derivatized as illustrated in Schemes 1-3.
Scheme 4
NT 0 ~h AE
NOI T° = NOY oo 2 ji he
H I Xi | — p
STW NH- Osa NF NH : i NH “~~ f ~N ) !
Boc ; ] INF as in A c IN N NH, Scheme lor2 EN H pas PS 0 0 iQ - A 5 v N 12
Boc H
Conditions: (a) (+)-Trans-2-(phenylsulfonyl)-3-phenyloxaziridine: (b) 4-(4-Boc- piperidine)-aniline: (c) (E10)2P(O)CH2CN
Any of the invention compounds of Formulas 1-VI may be prepared according to Schemes 1-4. wherein the synthesis of compounds 1. 51. 4. and 12, respectively. are illustrated. Those having skill in the art of organic chemistry will recognize that the starting materials may be varied. and additional steps may be employed to produce compounds encompassed by the present invention. as demonstrated by the following specific examples.
The disclosures in this application of all articles and references. including patents. are incorporated herein by reference.
The invention is illustrated further by the following detailed examples which are not to be construed as limiting the invention in scope or spirit to the specific procedures described in them. The starting materials and various ) intermediates may be obtained from commercial sources. prepared from 3 commercially available organic compounds. or prepared using well-known synthetic methods.
EXAMPLE 1 4-Amino-2-methanesulfanyi-pyrimidine-5-carboxylic acid etliy! ester
To a room temperature solution of 4-chloro-2-methanesulfanyl- pyrimidine-3-carboxylic acid ethyl ester (15.0 g. 65 mmol) in 200 mL of tetrahvdrofuran is added 25 mL of triethylamine followed by 35 mL of aqueous ammonium hvdroxide. After stirring at room temperature for 1.5 hours, an additional 30 mL of aqueous ammonium hydroxide is added. and stirring is continued for 1 hour. The reaction mixture is concentrated in vacuo and partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The organic layer is washed with brine. dried over magnesium sulfate. filtered. and concentrated in vacuo. Ethyl acetate and hexane are added. and the resultant solid is collected by filtration to provide 10.84 g (79%) of 4-amino-2-methanesulfanyl- pyvrimidine-5-carboxylic acid ethyl ester.
EXAMPLE 2 (4-Amino-2-methanesulfanyl-pyrimidin-5-vl)-methanol
A solution of 4-amino-2-methanesulfanyl-pyrimidine-3-carboxylic acid ethyl ester (13.36 g. 63 mmol) in 250 mL of tetrahydrofuran is added dropwise to a room temperature suspension of lithium aluminum hydride (3.82 g. 100 mmol) in 250 mL of tetrahvdrofuran. After 30 minutes. the reaction is cooled to 0°C, and : isopropyl alcohol is added until bubbling diminishes. The reaction 1s quenched with 15 mL of water. 15 mL of 15% NaOH. and 50 mL of water. and the mixture is stirred for 1 hour. The white precipitate 1s removed by filtration and washed with ethyl acetate. The filtrate is concentrated in vacuo and 3:1 hexane:ethy! acetate is added. The solids are collected. washed with 3:1 hexane:ethyl acetate, followed by hexane. The sohd is dissolved in ethvl acetate. and the solution 1s dried over magnesium sulfate. Filtration followed by concentration in vacuo gives 8.14 g (76%) of (4-amino-2-methanesulfanyl-pyrimidin-5-vl)-methanol.
Analysis calculated for C¢HgN3OS: . C. 42.09: H. 5.30: N. 24.54. 3 Found: C.42.31: H. 35.24: N.24.27.
EXAMPLE 5 d-Amino-2-methanesulfanyl-pyrimidine-5-carboxaldeliyde
To (4-amino-2-methanesultanyl-pyrimidin-3-vl)}-methanoi (8.14 g. 48 mmol) in 1 L of chloroform is added manganese oxide (33.13 g. 381 mmol).
The suspension is stirred at room temperature overnight then filtered through celite and washed with 300 mL of chioroform. The filtrate is concentrated in vacuo to give 8.14 g (quantitative yield) of 4-amino-2-methanesulfanyl- pyrimidine-3-carboxaldehyde. mp 185-187°C. Literature mp = 183-184°C. JOC. 1958:23:1738. 13 Analysis calculated for CgH7N30S:
C. 42.59: H. 4.17: N. 24.85.
Found: C. 42.84: H. 4.21: N. 24.75.
EXAMPLE 4
Ethyl 3-(4-Amino-2-methanesulfanyl-pyrimidin-5-yl)acrylate
To a room temperature solution of 4-amino-2-methanesulfanyl-pyrimidine- 5-carboxaldevde (4.08 g. 24.14 mmol) in 100 mL of tetrahydrofuran 1s added (carbethoxvmethvlene) triphenylphosphorane (10.80 g. 31 mmol). The reaction mixture is heated at reflux for 3 hours then stirred at room temperature overnight.
The reaction mixture is concentrated in vacuo. and the residue is purified by flash chromatography. eluting with 1:1 ethyl acetate:hexane. to provide 4.30 g (75%) of ethyl 3-(4-amino-2-methanesulfanyl-pyrimidin-3-vljacrylate: mp softens at 108°C.
Analysis calculated for CgH(13N300S:
C.50.19: H. 3.48: N. 17.36.
Found: C.30.22: H. 3.45: N. 17.24
EXAMPLE 5 ] 2-Methanesulfanyl-8H-pyrido[2,3-d, /[pyrimidin-7-one
To a room temperature solution of ethyl 3-(4-amino-2-methanesulfanyl ; pyvrimidin-3-yl)acrylate (368 mg. 1.53 mmol) in 3 mL of N.N- diisopropylethylamine is added 380 pL of 1 .8-diazabicyclo[5.4.0Jundec-7-ene.
The reaction mixture is heated at reflux for 3 hours then cooled to room temperature and concentrated. The residue 1s purified by flash chromatography eluting with ethyl! acetate. The fractions containing the product are partially concentrated in vacuo. and the solids are removed by filtration to provide 134 mg (45%) of 2-methanesulfanyl-8H-pvrido [2.3-d]pyrimidin-7-one. mp 269-271°C.
Analvsis calculated for CgH7N30S:
C. 49.73: H. 3.65: N. 21.75.
Found: C. 49.67: H. 3.46: N. 21.49.
EXAMPLE 6 7-Chloro-2-methylsulfanyl-pyrido[2,3-d [pyrimidine
A suspension of 1.0 g (5.2 mmol) of 2-methylsulfanyl-8H- pyrido[2.3-d]pyrimidin-7-one (Example 3) in 10 mL of phosphorus oxychloride is heated under reflux for 1 hour. The resulting solution is cooled and concentrated to give a solid. which is triturated with cold water and filtered to give 1.05 g of crude product. Recrystallization from acetonitrile gives 0.76 g (69%) of the product. mp 201-203°C.
MS (APCI) M+1: Caled 212.0: Found 212.0.
Anal. Calcd for CgHgC11S N53:
C.45.39: H. 2.86: N. 19.82.
Found: C. 45.53: H.2.90:N. 19.74.
EXAMPLE 7 x 2-Methyisulfanyl-pyrido[2,3-d[pyrimidin-7-vlamine
A suspension of 2.93 g (13.9 mmol) of 7-chloro-2-methylsulfanyl- pvrido[2.3-d]pyrimidine (Example 6) in 200 mL of isopropanol saturated with ammonia is sealed and heated at 40°C for 63 hours. The suspension is resaturated with ammonia and heated for another 18 hours at 40°C. The solid is collected by filtration and triturated with water to give 1.98 g (74.2%) of the product. mp >250°C. . MS (APC) M=+1: Caled 193.1: Found 193.0.
Anal. Calcd for CgHgN4S1:
C.49.98: H. 4.19: N. 29.14.
Found: C.30.14: H. 4.22: N. 29.04.
EXAMPLE 8 2-Methanesulfinyl-pyrido{2,3-d[pyrimidin-7-ylamine
A suspension of 10.63 g (55.3 mmol) of 2-methylsulfanyl- pyrido[2.3-d]pyrimidin-7-ylamine (Example 7) in 300 mL of dichloromethane and 300 mL of methanol is treated with 18.06 g (69.1 mmol) of (%)-trans-2- (phenylsulfony])-3-phenyloxaziridine and stirred overnight. The suspension is filtered to remove a small amount of solid. concentrated to approximately 25 mL, and diluted with ethvl acetate. The solid is collected by filtration to give 9.27 g (80.5%) of the product. mp 180°C (dec).
MS (APCI) M1: Calcd 209.0: Found 209.1.
EXAMPLE 9
N2-Phenyl-pyrido[2,3-d|pyrimidine-2,7-diamine
A suspension of 0.44 g (2.1 mmol) of 2-methanesulfinyl-pyrido[2.3- d]pvrimidin-7-ylamine (Example 8) and 0.39 mL (4.2 mmol) of aniline in 2 mL of dimethvlsulfoxide is heated at 100°C overnight. The resulting solution is cooled and poured into water. Ethyl acetate is added to the suspension. and the solid is collected by filtration. The solid is purified by flash chromatography. eluting with oradient of 0% to 20% methanol/dichloromethane during 30 minutes to give 0.14 g (29%) of the product. mp 255-260°C. : MS (APCI) M~1: Calcd 238.1: Found 238.1.
Anal. Caled for C13H11N3-0.18 Ho O:
C.64.92: H. 4.76: N. 29.12.
Found: C. 63.26: H. 4.75: N. 28.76.
EXAMPLE 10 1-tert-Butyl-3-(2-ph enylamino-pyrido[2,3-dpyrimidin-7-yl)-urea
To a solution of 0.1022 g (0.431 mmol) of N2-phenyl-pyrido[2.3- . d]pyrimidine-2.7-diamine (Example 9) in 2 mL of dimethylformamide. cooled in an ice bath. is added 0.019 g (0.47 mmol) of 60% sodium hydride. The resulting solution. cooled in an ice bath. is then treated with 0.054 mL (0.47 mmol) of tert-butyl isocyanate. The solution is stirred cold for 13 minutes. then at room temperature for 1 hour. The solution is poured into ice-water to give a solid which is collected by filtration and washed with hexane to give 0.0849 g (57.8%) of the product (compound 45). mp 227°C (dec).
MS (APCI) M~+1: Calcd 337.2: Found 337.1.
Anal. Caled for C1gHogNg01-0.27 HO:
C. 63.35; H. 6.07; N. 24.63.
Found: C. 63.73: H. 5.82: N. 24.20.
EXAMPLE 11 4-(4-Nitrophenyl)-piperazine-1-carboxylic acid tert-butyl ester
A suspension of 7.3 g (36 mmol) of 1-(4-nitropheny!)-piperazine and 6.94 mL (40 mmol) of ethyl-diisopropyl-amine in 75 mL of dichloromethane is treated with 8.69 g (40 mmol) of di-tert-butyl dicarbonate and stirred at room temperature overnight. The resulting solution is washed with saturated aqueous sodium bicarbonate. then with water. dried (magnesium sulfate). and concentrated.
The resulting material is purified by flash chromatography eluting with a gradient of 10% to 30% ethyl acetate/hexane during 10 minutes to give 8.62 g (77.5%) of the product. mp 136-140°C.
MS (APCI) M+1: Calcd 308.2: Found 308.2.
EXAMPLE 12 } 4-(4-Amino-phenyl)-piperazine-1-carboxylic acid tert-buryl ester
To a suspension of 1.46 g (4.8 mmol) of 4-(4-nitrophenyl1)-piperazine- ]-carboxvlic acid tert-butyl ester (Example 11) and 1 g of Raney Nickel in 50 mL of tetrahvdrofuran is added hvdrogen to an initial pressure of 34.5 psi. The reaction is shaken for 14 hours and then filtered. The filtrate is concentrated 10 give 1.29 g (97%) of the product as a solid. ’ MS (APCI) M+1: Calcd 278.2; Found 278.2. } Anal. Caled for C15H23N300:
C. 64.96: H. 8.36: N. 15.15.
Found: C.65.22: H. 8.38: N. 14.38.
EXAMPLE 15 4-[4-(7-Amino-pyrido[2,3-d[pyrimidin-2-ylamino)-ph enyl]-piperazine-
I-carboxylic acid tert-butyl ester
By substituting 4-(4-amino-phenyl)-piperazine-1-carboxvlic acid tert-butyl ester (Example 12) for aniline in Example 9. 0.0744 g (36.0%) of the product is obtained. mp 219-220°C.
MS (APCI) M +1: Caled 422.2: Found 422.2.
Anal. Caled for CooHy7N702:0.5 H2O:
C.61.38: H. 6.56: N. 22.77.
Found: C. 61.34: H. 6.30: N. 22.47.
EXAMPLE 14 4-{4- 7-(3-tert-Butvi-ureido)-pyrido[2,3-djpyrimidin-2- viaminol-phenyl}- piperazine-1-carboxylic acid tert-butyl ester
By substituting 4-[4-(7-amino-pyrido[2.3-d]pyrimidin-2-ylamino)- phenvl]-piperazine-1-carboxylic acid tert-butyl ester (Example 13) for NZ-phenyl- pyrido{2.3-d}pyrimidine-2.7-diamine in Example 10. 0.3354 2 (67.9%) of the product (compound 79) is obtained. mp 225°C (dec).
MS (APCI) M+1: Caled 521.3: Found 521.2.
Anal. Calcd for Co7H36NgO3:
C. 62.29: H. 6.97: N. 21.52. . Found: C. 62.33: H. 6.81: N. 21.43.
EXAMPLE 15 } I-tert-Butyl-3-[2-(4-piperazin-1-yl-phenyl amino)-pyrido[2,3-d[pyrimidin-7-yIJ- urea . To a suspension of 0.100 g (0.192 mmol) of 4-{4-[7-(3-tert-butyl-ureido)- 3 pvrido[2.3-d]pyrimidin-2-ylamino]-phenyl } -piperazine-1-carboxvlic acid tert- butyl ester (Example 14) in 2 mL of methanol is added 2 mL of 4 M hydrogen chloride dioxane to give a solution. The suspension is stirred at room temperature overnight. then diluted with diethyl ether. The material is collected by filtration to give 0.0941 g (93.4%) of the product (compound 1). mp 215°C (dec).
MS (APCI) M~1: Calcd 421.2: Found 421.1.
Anal. Calcd for C2oHogNg0;-2.10 HCI 1.51 HO:
C. 50.40: H. 6.37: N. 21.37: Cl (total). 14.20.
Found: C. 350.40: H. 6.18: N. 21.03: Cl (total). 14.33.
EXAMPLE 16 13 4-{4-[7-3-Cycloh exvl-ureido)-pyrido[2,3 -djpyrimidin-2-ylamino[-phenyl}- piperazine-1-carboxylic acid tert-butyl ester
By substituting cyclohexyl isocyanate tor tert-butyl isocyanate in
Example 14. 0.1463 g (70.4%) of the product (compound 80) is obtained. mp 241°C (dec).
MS (APCI) M~1: Caled 347.3: Found 347.4.
Anal. Caled for CogH3gNg03-0.28 H2O:
C.63.13: H. 7.04: N. 20.51.
Found: C.63.14: H. 6.81: N. 20.23.
EXAMPLE 17 1-Cyclohexyi-3-[2-(4-piperazin-1 -vi-phenylamino)-pyrido[2.3-d[pyrimidin- 7-vl]-urea . By substituting 4- (4.[7-(3-cvclohexyl-ureido)-pyrido[2.3-d]pyrimidin- 2-viamino}-phenyl}-piperazine-} -carboxvlic acid tert-butyl ester (Example 16) for 4-{3-[7-(3-tert-buryl-ureido )-pyrido[2.3-d]pyrimidin-2-ylamino}-phenyl b-
piperazine-1-carboxylic acid tert-butyl ester in Example 13. 0.0871 g (81.4%) of the product (compound 9) is obtained. mp 200°C (dec).
MS (APCI) M+1: Calcd 447.3: Found 447.3. . Anal. Calcd for Co4H39Ng0O1-2.55 HC1-2.82 H>O:
C. 48.83: H. 6.52: N. 18.98: Cl (total). 15.31.
Found: C. 48.83: H. 6.18: N. 18.89: Cl (total). 13.537.
EXAMPLE 18
N2-(4-Fluoro-3-methyl-phenyl )-pyrido[2,3-d[pyrimidine-2,7-diamine
By substituting 4-fluoro-3-methylaniline for aniline in Example 9. 0.2025 g (39.2%) of the product is obtained as a solid.
MS (APCI) M + 1: Caled 270.1: Found 270.0.
EXAMPLE 19
I-tert-Butyl-3-[2-(4-fluoro-3-methyl-phenylamino) -pyrido[2.3-d[pyrimidin- 7-vlJ-urea
By substituting N2.(4-fluoro-3-methyi-phenyl)-pyrido[2.3-d}pyrimidine- 2.7-diamine (Example 18) for N-2-phenyl-pyrido[2.3-d]pyrimidine-2.7-diamine in
Example 10. 0.0656 g (47.9%) of the product (compound 46) is obtained. mp 230°C (dec).
MS (APCI) M+1: Calcd 369.2: Found 369.1.
Anal. Caled for C1gH21FNgO1:
C.61.94: H. 5.75: N. 22.81.
Found: C.61.82: H. 35.73: N. 22.75.
EXAMPLE 20 } 1-(4-Chloro-phenyl)-3-[2-(4-fluoro-3-methyl-phenylamino)- 235 pyrido[2.3-d[pyrimidin-7-yvl|-urea : By substituting 4-chlorophenyl isocyanate for tertiarv-butyl isocyanate in
Example 19. 0.030 g (37%) of the product (compound 47) is obtained. mp >250°C.
MS (APC) M+1: Caled 423.1: Found 423.1.
Anal. Calcd for Co1H1gF1CliNgO1-0.23 H»O: . C. 59.07: H. 3.89: N. 19.68.
Found: C. 59.09; H.3.97: N. 19.65.
EXAMPLE 21 3 1-{2-{4-(4-Acetvl-piperazin-1 -vl)-phenviaminoj-pyrido[2.3-d[pyrimidin- 7-yl}-3-tert-buryl-urea
To a suspension of 0.143 g (0.277 mmol) of 1-tert-butyvi-3-[2-(4-piperazin- 1-vl-phenylamino)-pyrido{2.3-d]pyrimidin-7-y1j-urea (Example 15) in 5 mL of dichloromethane is added 0.19 mL (1.11 mmol) of ethyl-diisopropyl-amine. The suspension 1s cooled in an ice bath and treated with 0.024 mL (0.33 mmol) of acetyl chloride. The suspension is stirred at room temperature overnight, then filtered. The solid is washed with dichloromethane. The filtrate and washings are combined, washed with water. dried (magnesium sulfate). and concentrated. The material is purified by flash chromatography eluting with a gradient of 0% to 5% methanol/dichloromethane during 30 minutes to give 0.0674 g (51.8%) of the product (compound 5). mp 206-208°C (dec).
MS (APCI) M+1: Calcd 463.3: Found 463.3.
Anal. Caled for Co4H30Ng02-0.40 Ho O:
C.61.36: H. 6.61: N. 23.85.
Found: C.61.38: H. 6.37: N. 23.98.
EXAMPLE 22 4-{4-/ 7-(3-Isopropyl-ureido)-pyrido[2,3 -dJpyrimidin-2-ylaminoj-phenyl}- piperazine-1-carboxylic acid tert-butyl ester
By substituting isopropyl isocyanate for tert-butyl isocyanate in
Example 14. 0.909 g (69.9%) of the product is obtained as a solid.
MS (APCI) M~1: Caled 507.3: Found 507.4.
EXAMPLE 25
I-Isopropyl-3-[2-(4-piperazin-1-yl-phenviamin o)-pyridof2,3-dpyrimidin-7-yIf- ’ urea
By substituting 4-{4-[7-(3-isopropvl-ureido)-pyrido[2.3-d]pyrimidin- 3 2-vlamino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester (Example 22) for 4-4 4-[7-(3-tert-butyl-ureido)-pyrido[2.3-d]pyrimidin-2-ylamino]-phenyl }- piperazine-i-carboxylic acid tert-butyl ester in Example 13. 0.0287 ¢ (27.9%) of the product (compound 48) is obtained. mp 190°C (dec).
MS (APCl) M+1: Caled 407.2: Found 407.1.
Anal. Caled for C21H>gNg01-2.05 TFA-0.84 HHO:
C. 46.00: H. 4.57: XN. 17.10.
Found: C.46.00: H. 4.65: N. 17.09.
EXAMPLE 24
Cis-3.5-dimethyl-1-(4-nitro-phenylj-piperazine
A suspension of 6.74 g (47.8 mmol) of 4-fluoro-nitro-benzene and 10.91 g (95.5 mmol) of cis-2.6-dimethyl-piperazine is heated at 45°C for 1 hour. The reaction mixture is cooled and shaken with dichloromethane and water. The organic laver is dried (magnesium sulfate) and concentrated to give 11.62 g (>100%) of the product as a solid.
EXAMPLE 25
Cis-2.6-dimethyl-4-(4-nitro-phenylj-piperazine-1-carboxylic acid tert-butyl ester
By substituting cis-3.5-dimethy1-1-(4-nitro-phenyl)-piperazine (Example 24) for 1-(4-nitrophenyl)-piperazine in Example 11. 14.87 g (92.8%) of the product as a solid is obtained. : 25 EXAMPLE 26 4-(4-Amino-phenyl)-cis-2.6-dimethyl-piperazine-1 -carboxvliic acid tert-butyl! ) ester
By substituting cis-2.6-dimethy1-4-(4-nitro-phenyl)-piperazine- ]-carboxvlic acid tert-butyl ester (Example 25) for 4-(4-nitro-phenyl)-piperazine-
1-carboxvlic acid tert-butyl ester in Example 12.5.03 g (64.7%) of the product as a solid is obtained.
EXAMPLE 27 4-[4-(7-Amino-pyrido[2,3-d[pyrimidin -2-vlamino)-phenyl]-cis-2.6-dimetlyi- piperazine-1-carboxylic acid tert-bunyl ester
Bs substituting +4-14-amino-pheny! }-cis-2.6-dimethyvi-piperazine- 1-carboxvlic acid tert-butyl ester (Example 26) for aniline in Example 9. 0.6465 g (59.8%) of the product is obtained. mp 243°C (dec).
MS (APCI) M~1: Caled 450.3: Found 450.3.
EXAMPLE 28 4-{4-]7-(3-tert-Butyl-ureido)-pyrido{2,3-dJpyrimidin-2-ylamino [-phenyl}-cis- 2,6-dimethyl-piperazine-1-carboxylic acid tert-butyl ester
By substituting 4-[4-( 7-amino-pyrido{2.3-d]pyrimidin-2-ylamino)- phenyl]-cis-2.6-dimethyl-piperazine-1 -carboxvlic acid tert-butyl ester (Example 27) for NZ2-phenyl-pyrido[2.3-d]pyrimidine-2,7-diamine in Example 10, 0.1828 g (74.9%) of the product is obtained as a solid.
MS (APCI) M+1: Calcd 349.3: Found 549.4.
EXAMPLE 29
I-tert-Butvi-3-{2-[4-(cis-3,5-dimethyl-piperazin-1 -vl)-phenylamino/- pyrido[2,3-d|pyrimidin-7-yl}-urea
Byv substituting 4-14-[7-(3-tert-butyl-ureido)-pyrido[2.3-d]pyrimidin- 2-vlamino]-phenyl}-cis-2.6-dimethyl-piperazine-1-carboxylic acid tert-butyl ester (Example 28) for 4-4 4-[7-(3-tert-butyl-ureido)-pyrido[2.3-d]pyrimidin- 2-vlamino)-phenyl}-piperazine-1-carboxvlic acid tert-butyl ester in Example 15 is : 25 obtained 0.0910 g (92.9%) of the product (compound 49). mp 245°C (dec).
MS (APCI) M~1: Caled 449.3: Found 449.2.
EXAMPLE 30 4-{4-[7-(3-Cycloh exyl-ureido)-pyrido[2,3-d[pyrimidin-2-ylamino J-phenylj-cis- 2,6-dimethyl-piperazine-1-carboxylic acid tert-butyl ester } By substituting cyclohexyl isocyanate for tert-butyl isocvanate in 3 Example 28. 0.1156 g (60.8%) of the product is obtained as a solid.
MS (APCD) M1: Caled 375.3: Found 575.5.
EXAMPLE 31
I-Cyciohexyi-3-{2-{4-(cis-3,5-dimetl: yl-piperazin-1-yl)-phenyiamino]- pyrido[2,3-d[pyrimidin-7-ylj-urea
By substituting 4-{4-[7-(3-cyclohexyl-ureido)-pyrido[2.3-d]pyrimidin- 2-vlamino]-phenyl}-cis-2.6-dimethyl-piperazine-1-carboxylic acid tert-butyl ester (Example 30) for 4-{4-[7-(3-tert-butyl-ureido)-pyrido[2.3-d]pyrimidin-2- vlamino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester in Example 15. 0.1022 g of the product is obtained (compound 50). mp 228°C (dec).
MS (APCI) M+1: Calcd 475.2: Found 475.2.
EXAMPLE 52 4-{4-[7-(3-C3 velopentyl-ureido)-pyrido[2,3-d[pyrimidin-2-ylamino J-phenyl}- piperazine-1-carboxylic acid tert-butyl ester
To a solution of 0.130 g (0.36 mmol) of 4-[4-(7-amino-pyrido[2.3- d]pyrimidin-2-ylamino)-phenyl}-piperazine-1-carboxylic acid tert-butyl ester (Example 13) in 2 mL of dimethylformamide. cooled in an ice bath. is added 0.022 g (0.54 mmol) of 60% sodium hvdride. The cooled solution is stirred for 15 minutes. then treated with 0.088 g (0.54 mmol) of carbonyldiimidazole. The cooled solution is stirred for another 30 minutes. then treated with 0.071 mL (0.72 mmol) of cyclopentylamine. The resulting solution 1s stirred at room temperature for 1 hour. then added to cold water. The solid is collected by filtration to give a first crop of material. The aqueous filtrate is then extracted with ) dichloromethane. and the extracts are dried (magnesium sulfate) and concentrated to give a second crop of material. The 2 crops are combined and purified by flash chromatography. eluting with a gradient of 0% to 5% methanol/dichloromethane during 30 minutes to give 0.1159 g (60.4%) of the product as a solid.
MS (APCI) M+1: Caled 533.3: Found 533.4.
EXAMPLE 33
I-Cyclopentyl-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d[pyrimidin- 7-yl[-urea
By substituting 4-{4-[7-(3-cyclopentyl-ureido)-pyrido[2.3-d]p: rimidin- 2-vlamino}-phenyi;-piperazine-1-carboxylic acid tert-butyl ester {Example 32) for 4-{4-[7-(3-tert-butyi-ureido)-pyrido[2.3-d]Jpyrimidin-2-ylamino]-phenyl}- piperazine-1-carboxylic acid tert-butyl ester in Example 15. 0.0937 g (80.8%) of the product (compound 51) is obtained. mp 210-213°C (dec).
MS (APCI) M+1: Calcd 433.2: Found 433.2.
Anal. Calc for Co3H2gNgO1-2.49 HCI-1.65 H2O-0.1 dioxane:
C. 50.02: H. 6.21: N. 19.94: Cl] (total). 15.71.
Found: C. 49.89: H. 5.81: N. 19.74: Cl (total). 14.74.
EXAMPLE 34 1-(4-Amino-2-methylsulfanyl-pyrimidin-5-yl)-ethanol
To a suspension of 5.0 g (29 mmol) 4-amino-2-methylsulfanyl-pyrimidine- 3-carboxaldehvde (Example 3) in 150 mL of tetrahydrofuran. cooled by an ice bath. is added during 20 minutes. 23.2 mL of a 3.0 M methylmagnesium bromide solution in diethyl ether (69.4 mmol). After 1 hour at 0°C. another 23.2 mL of the 3.0 M methvlmagnesium bromide solution is added. and the suspension is allowed to come to room temperature and stirred overnight. The reaction is quenched with 100 mL of saturated aqueous ammonium chloride. and partitioned between water and ethyl acetate. The organic layer is dried (magnesium sulfate) and concentrated to give 5.24 g (96%) of the product, mp 140-142°C.
MS (APCI) M~1: Calcd 186.1: Found 185.9.
EXAMPLE 33 1-(4-Amino-2-methyisulfanyi-pyrimidin-5-yl)-ethanone
By substituting !-(+-amino-2-methylsulfanyl-pyrimidin-3-yl-ethanol (Example 34) for (4-amino-2-methvlsulfanvl-pyrimidin-5-vl)-methanol in
Example 3 and conducting the reaction at 80°C in toluene. 3.74 g (72%) of the product as a solid is obtained.
MS (APCI) M+1: Calcd 184.0: Found 183.9.
EXAMPLE 36 3 1-(4-Amino-2-methanesulfinyl-pyrimidin-5-yvl)-ethanone
B. substituting 1-{4-amino-2-methyisulfanyl-pynimidin-3-y i-ethanone (Example 33) for 2-methylsulfanyl-pyrido[2.3-d|pyrimidin-7-yiamine in
Example 8. 9.37 g (88%) of the product as a solid is obtained.
MS (APCI) M~1: Calcd 200: Found 200.
EXAMPLE 37 4-[4-(5-Acetvl-4-amino-pyrimidin-2-ylamino)-phenylj-piperazine-1-carboxylic acid tert-butyl ester
By substituting 1-(4-amino-2-methanesulfinyl-pyrimidin-3-y1 )-ethanone (Example 36) for 2-methanesulfinvl-pyrido[2.3-d]pyrimidin-7-ylamine in
Example 13. 4.04 g (63%) of the product as a solid 1s obtained.
MS (APCI) M+1: Caled 413: Found 413.
EXAMPLE 38 4-[4-(7-A mino-3-methyl-pyrido[2.3-d]pyrimidin-2-ylamino)-phenyl]-piperazine- 1-carboxvlic acid tert-butyl ester
To a suspension of 0.58 g (14.6 mmol) of 60% sodium hydride in 10 mL of tetrahvdrofuran. at 0°C. is added dropwise 2.58 g (14.56 mmol) of diethyl (cvanomethyl) phosphonate. The reaction mixture is stirred at 0°C for 5 minutes, then at room temperature for 20 minutes. The mixture is then cooled to 0°C and treated with 2 ¢ (4.85 mmol) of 4-[4-(5-acetyl-4-amino-pyrimidin-2-ylamino)- ‘ 25 phenvl]-piperazine-1-carboxylic acid tert-butyl ester (Example 57). The mixture is stirred at room temperature overnight. and then treated with water and saturated aqueous ammonium chioride. The resulting solid is collected by filtration and washed with ether to give 1.069 g (80%) of the product.
MS (APCI) M~1: Caled 436: Found 436.
EXAMPLE 39 4-{4-| 7-(3-Cyclohexyl-ureido)-3-metiyl-pyrido[2,3-djpyrimidin-2-ylamino|- phenyl}-piperazine-1-carboxylic acid tert-butyl ester . Bv substituting 4-[4-( 7-amino-3-methvl-pyrido[2.3-d]pyrimidin-2- 3 vlamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (Example 38) for 4-[4-(7-amino-pyrido[2.3-d]pyrimidin-2-ylamino)-phenyl]-piperazine-1 - carboxylic acid tert-butyl ester in Example 16. 0.199 g (42%) of the product as a solid is obtained.
MS (APCI) M~1: Caled 561: Found 561.
EXAMPLE 40 1-Cyclohexyl-3-[5-methy|-2-(4-piperazin-1-yl-phenviamino)- pyrido[2,3-d]pyrimidin-7-ylj-urea
By substituting 4- {4-[7-(3-cyclohexyl-ureido)-5-methyl-pyrido[2.3- d]pyrimidine-2-ylamino]-phenyi; piperazine-1-carboxylic acid tert-butyl ester (Example 39) for 4-{4-[7-(3-tert-butyl-ureido)-pyrido[2.3-d]pyrimidin-2- vlamino]-phenyl}-piperazine-1 carboxylic acid tert-butyl ester in Example 135, the product (compound 12) as a solid is obtained. mp 238°C (dec).
MS (APCI) M+1: Calcd 461: Found 461.
EXAMPLE 41 5-Methyl-2-methyisulfanyl-pyrido[2,3-d[pyrimidin-7-vlamine
By substituting I-(4-amino-2-methylsulfanyl-pyrimidin-3-yl)-ethanone (Example 33) for 4-[4-(3-acetyl-+-amino-pyrimidin-2-ylamino)-phenyl]- piperazine-1-carboxylic acid tert-butyl ester in Example 38. 0.97 g (85%) of the product as a solid is obtained.
MS (APCI) M~1: Caled 207: Found 207.
EXAMPLE 42 2-Methanesulfinyl-3-methyl-pyrido[2.3-d|pyrimidin-7-ylamine
By substituting 3-methyl-2-methylsulfanyl-pyrido[2.3-d]pyrimidin-7- vlamine (Example 41) for 2-methvisulfanyl-pyrido[2.5-d]pyrimidin-7-ylamine in
Example 8. 0.83 ¢ (83%) ot the product as a solid 1s obtained.
MS (APCI) M+1: Caled 223: Found 225.
EXAMPLE 43 4-[4-(7-A mino-5-methyl-pyrido(2,3-d, Ipyrimidin-2-ylamino)-phenyl |-piperazine-
I-carboxylic acid tert-butyl ester
By substituting 2-methanesulfinyl-3-methyl-pyrido[2.3-d]pyrimidin-7- viamine {Example 42) for 2-methanesulfinvi-pyrido{2.3-d]jpyrimidin-7-viamine in
Example 13. 0.33 g (20%) of the product as a solid 1s obtained.
MS (APCI) M~1. Calcd 436: Found 436.
EXAMPLE 44 4-{4-[7-(3 -tert-Butyl-ureido)-5-methyl-pyrido[2,3-d[pyrimidin-2-ylamino}- phenylj-piperazine-1-carboxylic acid tert-butyl ester
By substituting 4-[4-( 7-amino-35-methyi-pyrido[2.3-d]}pyrimidin-2- ylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (Example 43) for
N2-phenyl-pyrido[2.3-d]pyrimidine-2.7-diamine in Example 10. 0.17 g (45%) of the product as a solid is obtained.
MS (APCI) M+1: Calcd 335: Found 535.
EXAMPLE 45
I-tert-Butyl-3-[5-methyl-2-(4-piperazin-1-yl-ph enyvlamino)- pyrido[2,3-d|pyrimidin-7-yl/-urea
Byv substituting 4-{4-[7-(3-tert-butyl-ureido)-3-methyl-pyrido[2.3- d]pvrimidin-2-ylamino}-phenyl}-piperazine-1 -carboxylic acid tert-butyl ester (Example 44) for 4-{4-[7-(3-tert-butyl-ureido)-pyrido[2.3-d]pyrimidin-2- vlamino]-pheny!}-piperazine-1-carboxylic acid tert-butyl ester in Example 15, 0.070 g (72%) of the product (compound 4) as a solid is obtained. mp 230-232°C : 25 (dec).
MS (APCI) M+1: Calcd 435: Found 435.
EXAMPLE 46 6-Fluoro-2-methylsulfanyl-8H-pyrido{2,3-d[pyrimidin-7-one
A solution of 1.74 g (10.33 mmol) of (diethoxy-phosphoryl)-fluoro-acetic \ acid ethyl ester in 20 mL of tetrahydrofuran is cooled to -78°C and treated dropwise with 12.9 mL (20.65 mmol) of a 1.6 M solution of n-buty! lithium in hexanes. After stirring for 30 minutes at -78°C. the solution is treated with 1.74 g (10.33 mmol) of 4-amino-2-methylsulfanyl-pyrimidine-3-carboxaldehyde (Example 3). allowed to warm to room temperature. and stirred overnight. The reaction is treated with saturated aqueous ammonium chloride. then water. The solid is collected by filtration and washed with diethyl ether to give 2.01 g (92%) of the product.
MS (APCI) M+1: Caled 212: Found 212.
EXAMPLE 47 7-Chloro-6-f1 uoro-2-methyisulfanyl-pyrido{2,3-d[pyrimidine
By substituting 6-fluoro-2-methylsulfanyl-8 H-pyrido[2.3-d]pyrimidin- 7-one (Example 46) for 2-methylsulfanyl-8H-pyrido[2.3-d]pyrimidin-7-one in
Example 6 is obtained 1.86 g (85%) the product as a solid.
MS (APCI) M~1: Calcd 230. 232: Found 230. 232.
EXAMPLE 48 6-Fluoro-2-methyisulfanyl-pyrido[2,3-d[pyrimidine- 7-vlamine
By substituting 7-chloro-6-fluoro-2-methylsulfanyl-pyrido[2.3- d]pyrimidine (Example 47) for 7-chloro-2-methyisulfanyl-pyrido[2.3- d]pvrimidine in Example 7 is obtained 0.29 g (90%) of the product as a solid.
MS (APCI) M+1: Caled 211: Found 211. y 25 EXAMPLE 49 6-Fluoro-2-methanesulfinyi-pyridof2,3-dJpyrimidin-7-ylamine
By substituting 6-fluoro-2-methvlsulfanyl-pyrido[2.3-d]pyrimidin-7- vlamine (Example 48) for 2-methylsulfanyl-pyrido[2.3-d]pyrimidin-7-ylamine in
Example 8. 0.26 g (95%) of the product as a solid 1s obtained.
MS (APCI) M~1: Calcd 227: Found 227.
EXAMPLE 30 4-[4-(7-Amino-6-fluoro-pyrido[2,3 -d]pyrimidin-2-ylamino)-phenylf-cis- 2,6-dimethyl-piperazine-1-carboxylic acid tert-butyl ester . By substituting 6-fluoro-2-methanesulfinvl-pyrido[2.3-d]pyrimidin-7- 3 ylamine (Example 49) for 2-methanesulfinvl-pyrido[2.3-d]pyrimidin-7-vlamine in
Example 27. 0.040 g (63%) of the product as a solid is obtained.
MS (APC) M—1: Calcd 468: Found 468.
EXAMPLE 51 4-{4-[7-(3-C velohexyl-ureido)-6-fluoro-pyridof2.3-d Ipyvrimidin-2-yvlamino/- phenyl}-cis-2,6-dimetltyl-piperazine-1 -carboxylic acid tert-butyl ester
By substituting 4- [4-(7-amino-6-fluoro-pyrido[2.3-d]pyrimidin-2- vlamino)-phenyl}-cis-2.6-dimethyl-piperazine-1 -carboxvlic acid tert-butyl ester (Example 50) for 4-[4-(7-amino-pyrido[2.3-d]pyrimidin-2-ylamino)-phenyl]- piperazine-1-carboxylic acid tert-butyl ester in Example 16. 0.10 g (74%) of the product as a solid is obtained.
MS (APCI) M+1: Caled 595: Found 593.
EXAMPLE 32 1-Cyclohexyl-3-{2-[4-(cis-3 .5-dimethyl-piperazin-1-vl)-phenylamino/-6-fluoro- pyrido[2,3-d[pyrimidin-7-ylj-urea
By substituting 4-{4-[7-(3-cvclohexyl-ureido)-6-fluoro-pyrido[2.3- d]pyrimidin-2-ylamino]-phenyl }-cis-2.6-dimethyl-piperazine-1-carboxylic acid tert-butyl ester (Example 51) for 4- {4-[7-(3-tert-butyl-ureido)-pyrido[2.3- d]pyrimidin-2-ylamino}-phenyl }-piperazine-1-carboxylic acid tert-butyl ester in
Example 15. 0.060 g (75%) of the product (compound 52) as a solid 1s obtained. mp 227-229°C. ' MS (APCI) M=1: Caled 493: Found 493.
EXAMPLE 55 4-{4-[7-(3-C velopentyl-ureido)-S-methyl-pyrido[2,3-d[pyrimidin-2-ylamino/- phenyl}-piperazine-1 -carboxylic acid tert-butyl ester . By substituting 4-[4-( 7-amino-35-methyl-pyrido[2.3-d]pyrimidin-2- 3 vlamino )-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (Example 43) for 4-[4-(7-amino-pyrido[2.3-d]pyrimidin-2-vlamino)-phenyl]-piperazine-1- carboxylic acid tert-butyl ester in Example 32. 0.18 g (33%) of the product as a solid is obtained.
MS (APCI) M+1: Caled 547: Found 547.
EXAMPLE 54 1-Cyclopentyl-3-[5-methyl-2- (4-piperazin-1-yl-phenylamino)- pyrido[2.3-d[pyrimidin-7-y[]-urea
By substituting 4-{4-[7-( 3-cvclopentyl-ureido)-3-methyl-pyrido[2.3- d]pyrimidin-2-ylamino}-phenyl; -piperazine-1-carboxylic acid tert-butyl ester (Example 53) for 4-{4-[7-(3-tert-butyl-ureido)-pyrido[2.3-d]pyrimidin-2- vlamino]-pheny!}-piperazine-1-carboxylic acid tert-butyl ester in Example 15, 0.08 g (70%) of the product (compound 53) is obtained. mp 234°C (dec).
MS (APCI) M=1: Calcd 447: Found 447.
EXAMPLE 55 4-(4-{7-[3-(3-Hvdroxy-propyl y-ureidoJ-pvridof2,3-d Ipyrimidin-2-ylamino}- phenyl)-piperazine-1 -carboxvlic acid tert-buryl ester
By substituting 3-amino-1-propanol for cvclopentylamine. and sodium tertiary butoxide for sodium hydride in Example 32. 0.1295 g (52.2%) of the product as a solid is obtained.
MS (APC) M+1: Caled 523.3: Found 323.2.
EXAMPLE 56 ’ 1-(3-Hydroxy-propyl)-3-[2- (4-piperazin-1-yl-phenylamino)-pyrido [2.3-d[pyrimidin-7-yl[-urea
By substituting the product of Example 35 in Example 15. 0.1077 g of the product (compound 81) as a solid is obtained. mp 183°C (dec).
MS (APCI) M+1: Caled 423.2: Found 423.1.
EXAMPLE 57 . 4-{4-[7-(3-Cyclohexyl-3 -methyl-ureido)-pyrido[2,3-d[pyrimidin-2-ylamino /- phenyl}-piperazine-1 -carboxvlic acid tert-butyl ester 3 By substituting N-methvlcvelohexylamine for 3-amino-1-propanol in
Example 55. 0.1932 g (72.7%) of the product as a solid is obtained.
MS (APCI) M~1: Calcd 561.3: Found 561.2.
EXAMPLE 58 1-Cyclohexyl-1-methyl-3-[ 2-(4-piperazin-1-yl-phenylamino)-pyrido [2,3-d[pyrimidin-7-yl[-urea
By substituting the product of Example 57 in Example 15. 0.1645 g of the product (compound 65) as a solid is obtained. mp 177°C (dec).
MS (APCI) M+1: Caled 461.3: Found 461.2.
EXAMPLE 59 13 4-(4-{7-[3-((S)-1-Hydroxyvmethyl-3 -methyi-butyl)-ureido]-pyrido [2,3-d]pyrimidin-2-ylaminoj-ph enyl)-piperazine-1-carboxylic acid tert-butyl ester
By substituting (S)-(*)-leucinol for 3-amino-1-propanol in Example 55. 0.1048 g (39.1%) of the product as a solid is obtained.
MS (APCI) M~1: Calcd 365.3: Found 5635.3.
EXAMPLE 60 1-((S)-1 -Hydroxymetiyl-3-methyl-butyl)-3-[2-(4-piperazin-1-yl-phenylamino)- pyrido[2.3-d[pyrimidin-7-yl[-urea
By substituting the product of Example 59 in Example 15. 0.0802 g of the product (compound 83) as a solid is obtained. mp 185°C (dec). ’ MS (APCI) M+1: Caled 463.3: Found 465.2.
EXAMPLE 61 4-[4-(7-{[1-(4-Methyl-piperazin-1 -yl)-methanoyl J-aminoj-pyridof2,3- djpyrimidin-2-ylamino)-phen yl]-piperazine-1-carboxylic acid tert-butyl ester . By substituting N-methylpiperazine for 3-amino-1-propanol in 3 Example 55. the product as a solid 1s obtained.
MS (APCI) M-1: Calcd 548.3: Found 348.3.
EXAMPLE 62 4-Methyl-piperazine-1-carboxylic acid [2-(4-piperazin-1-y{-phenylaminoj- pyridof2,3-d]pyrimidin-7-y], '[-amide
By substituting the product of Example 61 in Example 15. 0.1194 g of the product (compound 84) as a solid is obtained. mp 200°C (dec).
MS (APCI) M+1: Calcd 448.3: Found 448.2.
EXAMPLE 65 4-(4-{7-[(1-Morpholin-4-yi-methan oyl)-amino]-pyridof2,3-d[pyrimidin-2- vlaminoj-phenyl)-piperazine-1 -carboxylic acid tert-butyl ester
By substituting morpholine for 3-amino-1-propanol in Example 35. the product as a solid is obtained.
MS (APCI) M~1: Calcd 535.3: Found 535.2.
EXAMPLE 64
Morpholine-4-carboxylic acid [2-(4-piperazin-1 -vil-phenylamino)-pyrido(2,3- djpyrimidin-7-yl[-amide
By substituting the product of Example 63 in Example 15. 0.1132 g of the product (compound 85) as a solid is obtained. mp 190°C (dec).
MS (APCI) M=1: Caled 433.2: Found 435.2.
EXAMPLE 65 ’ 4-{4-[7-(3,3 -Dipropyi-ureido)-pyridof 2,3-djpyrimidin-2-ylaminof-phenyl}- piperazine-1-carboxylic acid tert-butyl ester
By substituting dipropylamine for 3-amino-1-propanol in Example 35. the product as a solid is obtained.
MS (APCI) M~1: Calcd 549.3: Found 549.3.
EXAMPLE 66 . 3-[2-(4-Piperazin-1 -yl-phenylamino)-pyrido[2,3-dpyrimidin- 7-vlj-1,1-dipropy! urea
By substituting the product of Example 65 in Example 13. 0.1278 g of the product (compound 86) as a solid 1s obtained. mp 190°C (dec).
AMS (APC) M+1: Caled 449.3: Found 449.2.
EXAMPLE 67 4-[4-(7-{[1-(4-Boc-piperazin-1-yl)-meth anoyl]-aminoj-pyrido[2,3-d[pyrimidin-2- vlamino)-phenylj-piperazine-I carboxylic acid tert-butyl ester
Bv substituting Boc-piperazine for 3-amino-1-propanol in Example 55, the product as a solid is obtained.
MS (APCI) M~1: Caled 634.3: Found 634.3.
EXAMPLE 68
Piperazine-I-carboxylic acid [2-(4 -piperazin-1-yl-phenylamino)-pyrido(2,3- dlpyrimidin-7-yl]-amide
Bv substituting the product of Example 67 in Example 135. 0.0342 g of the product (compound 87) as a solid is obtained. mp 220°C (dec).
MS (APCI) M+1: Caled 434.2: Found 454.2.
EXAMPLE 69 4-(4-{7-[3-((R)-1-H ydroxymethyl-2-methyl-propyl)-ureido|-pyrido[2,3 - dpyrimidin-2-ylamino}-phenyl)-piperazin e-1-carboxyviic acid tert-butyl ester
By substituting (R)-valinol for 3-amino-1-propanol in Example 33. the : product as a solid is obtained. 23 MS (APCI) M+1: Caled 351.3: Found 531.3.
EXAMPLE 70 1-((R)-1-Hydroxymeth yl-2-methyl-propyl)-3-[2-(4-pip erazin-1-yl-phenylamino)- pyridof2,3-d[pyrimidin- 7-ylf-urea . By substituting the product of Example 69 in Example 15. 0.0639 g of the product (compound 88) as 2 solid is obtained. mp 200°C (dec).
MS (APCI) M=1: Caled 451.3: Found 451.2.
EXAMPLE 71 4-(4-{7-[3,3-Bis-(2-hydroxy-ethyl)-ureido j-pyridof2,3-djpyrimidin-2-ylaminoj- phenyl)-piperazine-1 -carboxylic acid tert-butyl ester
By substituting diethanolamine for 3-amino-1-propanol in Example 55, the product as a solid is obtained.
MS (APCI) M+1: Caled 553.3: Found 553.2.
EXAMPLE 72 1,1-Bis-(2-hydroxy-eth yl)-3-[2-(4-piperazin-1-yl-phenylamino )-pyridof2,3- d]pyrimidin-7-yl]-urea
By substituting the product of Example 71 in Example 15. 0.0916 g of the product (compound 89) as a solid is obtained. mp 185°C (dec).
MS (APCI) M=+1: Calcd 453.2: Found 453.2.
EXAMPLE 73 6-Bromo-2-methylsulfanyl-8H-pyrido[2,3-d[pyrimidin-7-one
To 5.00 g (25.9 mmol) of 2-methanesuifanyi-8H-pyrido{2.3-d}pyrimidin- 7-one (Example 5) in 130 mL of DMF is added 5.00 g (28.1 mmol) of
N-bromosuccinimide. The resulting suspension is stirred at room temperature overnight and concentrated. The solid 1s triturated with hot water. then washed : 25 with isopropanol to give 5.39 g (79.4%) of the product as a solid. mp 266-270°C.
EXAMPLE 74 6-Bromo-7-chloro-2-methyisulfanyl-pyrido[2,3-d [pyrimidine
By substituting the product of Example 73 in Example 6. 2.73 g (97.2%) ot the product is obtained as a solid.
MS (APCI) M+1: Caled 289.9: Found 289.8.
EXAMPLE 75
R 6-Bromo-2-methyisulfanyl-pyrido[2,3-d Ipyrimidin-7-ylamine
By substituting the product of Example 74 in Example 7. 2.09 g (82.9%) of the product is obtained as a solid.
MS (APCI) M=1: Caled 271.0: Found 270.8.
EXAMPLE 76 6-Bromo-2-methanesulfinyl-pyrido[2,3-dpyrimidin- 7-vlamine
By substituting the product of Example 75 in Example 8. 1.81 g (81.9%) of the product is obtained as a solid, mp 245°C (dec).
MS (APCI) M+1: Calcd 287.0: Found 286.8.
EXAMPLE 77 4-[4- 7-Amino-6-bromo-pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl|-piperazine-
I-carboxvlic acid tert-butyl ester
By substituting the product of Example 76 in Example 13. 1.40 g (44.4%) of the product is obtained as a solid.
MS (APCI) M+1: Calcd 500.1: Found 500.0.
EXAMPLE 78 4-44-[6-Bromo-7-(3-cyclohexyl-ureido)-pyrido[2,3-d]pyrimidin-2-ylamino]- phenylj-piperazine-1 -carboxylic acid tert-butyl ester
By substituting the product of Example 77 in Example 16. 0.1160 g (46.4%) of the product is obtained as a solid.
MS (APCI) M+1: Calcd 623.2: Found 625.1.
EXAMPLE 79 23 1 _[6-Bromo-2-(4-piperazin-i-yl-phenylamino)-pyrido[2,3-dJpyrimidin- 7-yl]-3- cyclohexyl-urea
By substituting the product of Example 78 in Example 15. 0.0886 p (77.0%) of the product (compound 55) 1s obtained as a solid. mp 193°C (dec).
MS (APCI) M+1: Caled 525.2: Found 525.1.
Anal. Calcd for Co4Ho9BriNgOy-1.64 H>0-1.83 HCL:
C. 46.37: H.5.53: N. 18.02: CL. 10.44. ‘ Found: C. 46.53: H.5.34:N. 17.73: C1. 10.15. 3 EXAMPLE 80 4-{4-[6-Bromo-7-(3-tert-burvl-ureido)-pyrido/2,3-d pyrimidin-2-viamino/- phenyl}-piperazine-1-carboxylic acid tert-bury! ester
By substituting the product of Example 77 in Example 10.0.2571 ¢ (42.9%0) of the product is obtained as a solid.
MS (APCI) M+1: Caled 599.2: Found 599.2.
EXAMPLE 81 1-[6-Bromo-2-(4-piperazin-1-yl-phenylamino) -pyrido[2,3-d[pyrimidin-7-yl}-3- tert-butyl-urea
By substituting the product of Example 80 in Example 15. 0.0481 g of the product (compound 91) is obtained as a solid.
MS (APCI) M=1: Calcd 499.2: Found 499.0.
EXAMPLE 82 4-{4-[6-Bromo-7-(3-methyl-ureido)-pyrido{2,3-d[pyrimidin-2-ylamino]-phenyl}- piperazine-1-carboxylic acid tert-butyl ester
By substituting the product of Example 77 and methylamine in
Example 32. 0.170 g (29.9%) of the product is obtained as a solid.
MS (APCI) M+1: Calcd 557.2: Found 557.1.
EXAMPLE 83 . 1-[6-Bromo-2-(4-piperazin-1-yl-phenylamino)-p. yrido[2,3-d[pyrimidin-7-yl]-3- methvl-urea
By substituting the product of Example 82 in Example 15. 0.0963 g (69%) of the product (compound 93) is obtained as a solid.
MS (APCI) M+1: Caled 457.1: Found 457.1.
Anal. Caled for C1gH21BriNg0O1-3 HCI-3 Ha 0:
C. 36.76: H. 4.87: N. 18.05: C1. 17.13: H»0. 8.71.
Found: C. 36.49: H.4.35:N. 17.52: Cl. 15.79: HO. 8.12. >
EXAMPLE 84 3 4-[4-(7-Amino-6-bromo-pyrido[2,3-d, [pyrimidin-2-ylaminoj-phenylj-cis-2,6- dimethyi-piperazine-1-carboxylic acid tert-butyl ester
By substituting the product of Example 76 in Example 27. 2.10 g (63.1%) of the product is obtained as a solid.
MS (APCI) M~1: Caled 528.2: Found 528.2.
EXAMPLE 85 4-{4-[6-Bromo-7-(3-tert-butvl-ureido)-pyrido[2,3-d, [pyrimidin-2-ylaminof- phenylj-cis-2,6-dimethyl-piperazine-1 -carboxvlic acid tert-butyl ester
By substituting the product of Example 84 in Example 10. 0.1725 g (72.6%) of the product is obtained as a solid.
MS (APCI) M~1: Caled 627.2: Found 627.2.
EXAMPLE 86 1-{6-Bromo-2-{4-(cis-3.5-dimethyl-piperazin-1-yi) -phenylaminof-pyridof2,3- d]pyrimidin-7-yl}-3-tert-butyl-urea
By substituting the product of Example 85 in Example 15. 0.1593 ¢ (96.0%) of the product (compound 94) is obtained as a solid. mp 202°C (dec).
MS (APCI) M=1: Caled 527.2: Found 327.2.
Anal. Caled for Co4H31BriNg0O;-2.55 HCI-1.70 Ho O:
C.44.28:H. 3.72: N. 17.21: C1. 13.89.
Found: C.44.28:H. 3.72: N. 17.09: C1. 12.49.
EXAMPLE 87 4-{4-[6-Bromo- 7-(3-cyclohexyl-ureido)-pyrido[2,3-d]pyrimidin-2-ylaminoj- ) phenyl}-cis-2,6-dimethyl-piperazin e-1-carboxylic acid tert-butyl ester ‘ By substituting the product of Example 84 in Example 16. 0.1750 g 3 (70.7%) of the product is obtained as a solid.
MS (APCI) M+1: Caled 632.3: Found 633.3.
EXAMPLE 88 1-{6-Bromo-2-[4-(cis-3,5 -dimethyi-piperazin-I1-yij-phenviaminoj-pyridof2,3- djpyrimidin-7-yl}-3-cyclohexyl-urea
By substituting the product of Example 87 in Example 13. 0.1614 g (95.4%) of the product (compound 95) is obtained as a solid. mp 198°C (dec).
MS (APCI) M+1: Caled 553.2: Found 353.2.
Anal. Caled for CogH33Ng0O1Br-2.76 HC1.2.02 HHO:
C.45.22: H. 5.81: N. 16.23: Cl. 14.17.
Found: C.45.23:H. 35.82: N. 16.08: CL 13.53.
EXAMPLE 89
N2 -(4-Fluoro-phenyl)-pyridof2,3 -d]pyrimidine-2,7-diamine
By substituting 4-fluoroaniline in Example 9. 1.1529 g (43.2%) of the product is obtained as a solid. mp 245-248°C.
MS (APCI) M~1: Caled 256.1: Found 255.9.
EXAMPLE 90 1-[2-(4-Fluoro-phenylamin 0)-pyrido[2.3-d[pyrimidin-7-yl[-3-(3 -morpholin-4-yl- propyl)-urea
By substituting the product of Example 89 and 3-morpholin-4-y1- i 25 propylamine in Example 32. 0.1465 ¢ (58.6%) of the product (compound 96) is . obtained as a solid. mp 233-256°C.
MS (APCI) M+1: Calcd 426.2: Found 426.1.
Anal. Calcd for Co Ho4FN702: . C. 59.28: H. 5.69: N. 23.04.
Found: C. 39.18: H. 5.66: N. 23.04.
EXAMPLE 91 3 1-[2-(4-Fluoro-phenylamino)-pyrido[2 3-d]pvrimidin-7-yl]-3-(2-hydroxy-ethyl)- urea
By substituting the product of Example 89 and 2-hvdroxy-ethylamine in
Example 32. 0.0811 g (40.3%) of the product (compound 97) is obtained as a solid. mp 238-240°C.
MS (APCI) M~1: Calcd 343.1: Found 345.1.
Anal. Calcd for C1gH15F1NgO2:
C.56.14; H. 4.42: N. 24.55.
Found: C. 35.82: H. 4.52: N. 24.15.
EXAMPLE 92 1-(2-Amino-ethyl)-3-[2-(4-fluoro-ph enylamino)-pyrido[2,3-d[pyrimidin-7-yl]- urea
By substituting the product of Example 89 and ethylenediamine in
Example 32. 0.1000 g (49.3%) of the product (compound 98) is obtained as a solid. mp 217-220°C.
MS (APCI) M+1: Caled 342.1: Found 342.0.
Anal. Calcd for C1gH6F1N701-0.2 H2O:
C.55.71; H. 4.79: N. 28.42.
Found: C.35.72: H. 4.57: N. 28.07.
EXAMPLE 95 23 I-(2-Dimethylamino-ethyl)-3-[2-(4-fluoro-phenylamino)-pyrido[2,3- , djpyrimidin-7-yl[-urea
By substituting the product of Example 89 and 2-dimethylamino- ethvlamine in Example 32. 0.0778 g (35.8%) of the product (compound 99) is obtained as a solid. mp 231-255°C.
MS (APCI) M+1: Caled 370.2: Found 370.0.
Anal. Calcd for C1gHyoF |N701:
C. 58.53; H. 5.46; N, 26.54. ‘ Found: C. 58.39: H.5.51:N. 26.26. h, EXAMPLE 94 3,3-Dimethyi-1-(4-nitro-phenyi)-piperazine
By substituting 2.2-dimethyl-piperazine in Example 24. 26.43 g (88.4%) of the product is obtained as a solid.
MS (APCI) M+1: Calcd 236: Found 236.
EXAMPLE 95 2-2-Dimethyl-4-(4-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
Bv substituting the product of Example 94 in Example 11. 38 g (93%) of the product is obtained as a solid.
MS (APCI) M+1: Caled 336: Found 336.
EXAMPLE 96 4-(4-Amino-phenyl)-2,2-dimethyl-piperazine-1-carboxylic acid tert-butyl ester
By substituting the product of Example 95 in Example 12. 27 g (78%) of the product is obtained as a solid.
MS (APCI) M+1: Calcd 306: Found 306.
EXAMPLE 97 4-[4-(7-Amino-6-fluoro-pyrido[2,3-d Ipyrimidin-2-ylamino)-phenyl]-2,2- dimethyl-piperazine-1-carboxylic acid tert-butyl ester
By substituting the product of Example 96 in Example 50. 0.4346 g . (59.0%) of the product is obtained as a solid.
MS (APCI) M+1: Calcd 468.2: Found 468.5.
EXAMPLE 98 4-{4-[7-(3-Cyclohexyi-ureido)-6-fluoro-pyrido[2,3-d[pyrimidin-2-ylamin of- phenyl}-2,2-dimethyl-piperazine-1-carboxylic acid tert-butyl ester ‘ By substituting the product of Example 97 in Example 16. 0.170 g (31.2%) of the product is obtained as a solid.
MS (APCI) M=1: Calcd 593.2: Found 393.4.
EXAMPLE 99 1-Cyclohexyi-3-{2-[4-(3,3-dimethyi-piperazin-i-yi)-phenylaminof-6-fliioro- pyridof2,3-d[pyrimidin-7-yl}-urea
By substituting the product of Example 98 in Example 15. 0.040 g of the product (compound 100) is obtained as a solid.
MS (APCI) M~1: Calcd 493.3; Found 493.2.
EXAMPLE 100 4-[4-(7-Amino-6-fluoro-pyrido[2,3-d[pyrimidin-2-ylamino)-phenyl]-piperazine- 13 I-carboxylic acid tert-butyl ester
By substituting the product of Example 12 in Example 50. 0.2017 g (29.7%) of the product is obtained as a solid.
MS (APCI) M+1: Calcd 440.2: Found 440.2.
EXAMPLE 101] 4-{4-[7-(3-Cyclohexyl-ureido)-6-fluoro-pyrido(2.3-d[pyrimidin-2-ylamino/- phenyl}-piperazine-1-carboxylic acid tert-butyl ester
By substituting the product of Example 100 in Example 16. 0.2036 ¢ (78.6%) of the product is obtained as a solid.
MS (APCI) M+1: Caled 565.3: Found 565.3.
EXAMPLE 102 : 1-Cyclohexyl-3-[6-fluoro-2-(4-piperazin-1-yl-phenylamino)-pyridof2,3- dlpyrimidin-7-yl]-urea
By substituting the product of Example 101 in Example 15. 0.1084 g (96.0%) of the product (compound 11) is obtained as a solid.
MS (APCI) M+1: Calcd 465.2: Found 4635.2.
Anal. Caled for Co4HogFNg01-2.75 HCI-3.5 HO:
C. 45.91; H. 5.10: N. 17.85: CL. 15.53: H»O, 10.04. ) Found: C.46.20: H. 5.86: N. 17.45: CL. 15.22: H7O. 8.97. 3 EXAMPLE 103 4-{4- 7-(3-tert-Butyl-ureido)-6-fluoro-pyrido[2,3-d[pyrimidin-2-ylamino/- phenylj-cis-2,6-dimethy! piperazine-1 -carboxylic acid tert-butyl ester
By substituting the product of Example 50 in Example 10. 0.070 g (17.5%) of the product is obtained as a solid.
MS (APCI) M+1: Calcd 567.3: Found 567.3.
EXAMPLE 104
I-tert-Butyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1 -vl)-plhenylamino]-6-fluoro- pyrido[2,3-d[pyrimidin-7-y[}-urea
By substituting the product of Example 103 in Example 15. 0.0585 g of the product (compound 102) is obtained as a solid.
MS (APCI) M+1: Caled 467.3: Found 467.5.
EXAMPLE 105 1-/4-(4-Nitro-phenyl)-piperazinylj-ethanone
To a solution of 3.0 g (24.1 mmol) of 1-(4-nitro-phenyl)-piperazine in 100 mL of dichloromethane was added 5.04 mL (28.9 mmol) of diisopropyl- ethvlamine. The solution is cooled in an ice-bath. treated with 1.89 mL (26.5 mmol) of acetvl chloride. and stirred at room temperature overnight. The reaction is washed successively with water. 0.5 M HC. saturated sodium hvdrogen carbonate. and brine. and dried over magnesium sulfate. and 23 concentrated to give 5.91 g (98.5%) of the product as a solid. } MS (APCI) M+1: Calcd 250.1: Found 250.0.
EXAMPLE 106 ) 1-[4-(4-A mino-phenyl)-piperazin-I -ylj-ethanone
By substituting the product of Example 105 in Example 12. 4.35 g (84.1%) : of the product is obtained as a solid.
MS (APCI) M~1: Caled 220.1: Found 220.1.
EXAMPLE 107 1-{4-[4-(7-A mino-pyrido[2,3-d[pyrimidin-2-ylamino)-phenyl]-piperazin- 1-yl}- ethanone
By substituting the product of Example 106 in Example 9. 0.1829 ¢ (50.1%) of the product is obtained as a solid.
MS (APCI) M+1: Caled 364.2: Found 364.2.
Anal. Caled for C1gH~N701-1.0 HO:
C, 59.46: H. 6.11: N. 25.55.
Found: C. 59.51: H. 6.03: N. 25.28.
EXAMPLE 108 1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino[-pyrido[ 2,3-dJpyrimidin-7-yl}-3- (3-morpholin-4-yl-propyl)-urea
By substituting the product of Example 107 and 3-morpholin-4-yl- propylamine in Example 32. 0.0338 (22.6%) of the product (compound 103) is obtained as a solid. mp 222-225°C (dec).
MS (APCI) M—+1: Calcd 534.3: Found 534.2.
Anal. Calcd for C77H35N903-0.5 HO:
C. 59.76: H. 6.69: N. 23.25.
Found: C. 59.74: H. 6.33: N. 23.33.
EXAMPLE 109 . 6-Chloro-2-methyisulfanyl-8H-pyrido[2,3-d[pyrimidin-7-one
By substituting N-chlorosuccinimide in Example 74. 0.3700 g (31.4%) of the product is obtained as a solid. mp 264-266°C (dec).
MS (APCI) M=1: Calcd 228.0: Found 227.9.
EXAMPLE 110 6, 7-Dichioro-2-methylsulfanyl-pyrido[2,3-d|pyrimidine
By substituting the product of Example 109 in Example 6. 0.6334 g (86.5%) of the product is obtained as a solid.
MS (APCI) M+1: Calcd 246.0; Found 245.8.
EXAMPLE 11 6-Chloro-2-methyisulfanyl-pyrido[2,3-d[pyrimidin-7-ylamine
By substituting the product of Example 110 in Example 7. 0.38 g (63%) of the product is obtained as a solid.
MS (APCI) M+1: Calcd 227.0: Found 226.9.
EXAMPLE 112 6-Chloro-2-methanesulfinyl-pyrido[2,3-d[pyrimidin-7-ylamine
By substituting the product of Example 111 in Example 8. 0.2328 g (57.1%) of the product is obtained as a solid. mp 260-262°C.
MS (APCI) M+1: Calcd 243.0; Found 242.9.
EXAMPLE 113 4-[4-(7-Amino-6-chloro-pyrido[2,3 -d|pyrimidin-2-ylamino)-phenyl|-cis-2,6- dimethyl-piperazine-1-carboxylic acid tert-butyl ester
By substituting the product of Example 112 in Example 27. 0.22 g (49%) of the product is obtained as a solid.
MS (APCI) M+1: Calcd 484.2: Found 484.2.
EXAMPLE 114 4-{4-[7-(3-tert-B utyl-ureido)-6-chloro-pyrido[2,3-d[pyrimidin-2-ylaminoj- . phenyl}-cis-2,6-dimethyl-piperazine-1 -carboxylic acid tert-butyl ester
By substituting the product of Example 113 in Example 10. 0.0995 ¢ ‘ (39.2%) of the product is obtained as a solid.
EXAMPLE 115 . I-tert-Butyl-3-{6-chioro-2-[4-(cis-3,5 -dimethyl-piperazin-1-yl)-phenylaminoj- pyrido]2,3-djpyrimidin-7-yl}-urea ’ By substituting the product of Example 114 in Example 15. 0.0995 g of the product (compound 104) is obtained as a solid. mp 205°C (dec).
MS (APCI) M+1: Calcd 483.2: Found 483.2.
EXAMPLE 116
Methyl-(2-methylsulfanyl-pyrido[2,3-dfpyrimidin- 7-yi)-amine
By substituting methylamine in Example 7. 1.46 g (30.0%) of the product is obtained as a solid.
MS (APCI) M+1: Caled 207.1: Found 206.9.
EXAMPLE 117 (2-Methanesulfinyl-pyrido[2,3-dJpyrimidin-7-yl)-meth yl-amine
By substituting the product of Example 116 in Example 8. 1.31 g (83.4%) of the product is obtained as a solid. mp 185°C.
MS (APCI) M+1: Caled 223.1: Found 223.0.
EXAMPLE 118 4-[4-(7-Methylamino-pyrido[2.3-d, Ipyvrimidin-2-ylamino)-phenyl]-piperazine-1- carboxylic acid tert-butyl ester
By substituting the product of Example 117 in Example 13. 0.4934 ¢ (62.9%) of the product is obtained as a solid.
MS (APCI) M+1: Calcd 436.2: Found 436.2.
EXAMPLE 119 ) 4-{4-[7-(3-Cyclohexyl-1 -methyi-ureido)-pyrido[2,3-d[pyrimidin-2-yl|-phenyl}- piperazine-1-carboxylic acid tert-butyl ester
By substituting the product of Example 118 in Example 16. and using acetonitrile as solvent and no base. 0.8333 g (78.8%) of the product is obtained as a solid.
MS (APCl) M+1: Calcd 361 3: Found 361.5.
EXAMPLE 120 3-Cyclohexyi-1-methyi-1 -[2-(4-piperazin-1-yl-phenylamino) -pyridof2,3- djpyrimidin-7-yl]-urea , By substituting the product of Example 119 in Example 15. 0.2548 ¢ (36.0%) of the product (compound 70) is obtained as a solid. mp 169-175°C.
MS (APCI) M=1: Calcd 461.3: Found 461.2.
Anal. Calcd for Co5H32Ng01-0.25 H2O.
C. 64.56: H. 7.04: N. 24.09.
Found: C. 64.57: H, 7.01: N. 23.98.
EXAMPLE 121 3-Cyclohexyl-1-{2-{4-(cis-3 ,5-dimethyl-piperazin-1-vl)-phenylaminof-pyrido[2,3- d]pyrimidin-7-yl}-1-methyl-urea
Using the general procedure by which Example 120 is synthesized. 0.1366 g (95.6%) of the product (compound 106) is obtained as a solid, mp 170°C (dec).
MS (APCI) M+1: Calcd 489.3: Found 489.3.
Anal. Calcd for Co7H36Ng01-3.32 H20-2.69 HCL:
C. 50.16: H. 7.07: N. 17.33: CL. 14.75.
Found: C. 350.36: H. 6.98: N. 16.97: C1. 15.07.
EXAMPLE 122 3-Cyclohexyl-1-ethyl-1-[2-(4-piperazin-1-yl-ph enviamino)-pyrido{2,3-d] pyrimidin-7-ylf-urea
Using the general procedure by which Example 120 is synthesized. 0.118 g (94%) of the product (compound 107) is obtained as a solid.
MS (APCI) M+1: Calcd 475.3: Found 473.3.
Anal. Caled for CogH34Ng01-3.0 HCI-0.3 diethylether: ’ C. 53.89: H. 6.63: N. 18.48.
Found: C. 33.75: H. 6.96: N. 18.57.
EXAMPLE 123 3-tert-Butyi-1-{2-[4-(cis-3 ,5-dimethyl-piperazin-1-yl)-phenylamino J-pyrido[2,3- djpyrimidin-7-yl}-1-ethyl-urea . Using the general procedure by which Example 15 is synthesized. 0.022 g (56%) of the product (compound 108) is obtained as a solid.
MS (APCD) M=1: Calcd 477.3: Found 477.3.
EXAMPLE 124 -Metiryi-3-{5-methyl-2-{4-piperazin- I-pl-phenylamino)-pyrido[2,3-d[pyrimidin- 7-yl]-urea
Using the general procedure by which Example 40 is synthesized. the product (compound 64) is obtained as a solid, mp 204-206°C (dec).
MS (APCI) M+1: Calcd 393: Found 393.
EXAMPLE 125 1-Ethyl-3-[5-meth yI-2-(4-piperazin-1-yl-ph enyviamino)-pyrido[2,3-d[pyrimidin- 7-ylJ-urea
Using the general procedure by which Example 40 is synthesized. the product (compound 28) is obtained as a solid. mp 220-222°C.
MS (APCI) M+1: Caled 407: Found 407.
EXAMPLE 126 1-{5-Methyl-2-(4-piperazin-1 -yl-phenylamino)-pyrido[2,3-d[pyrimidin-7-yl}- 3-propyl-urea
Using the general procedure by which Example 40 is synthesized, the product (compound 111) is obtained as a solid. mp 223-225°C.
MS (APCI) M~+1: Calcd 421: Found 421.
EXAMPLE 127
N,N-Dimethyl-N -{5-metlyl-2-{[4-(1 -piperazinyl)phenylf-aminoj-pyridof2,3- djpyrimidin-7-yl-sulfamide . Using the general procedure by which Example 40 is synthesized. but using dimethyl sulfamyl chloride rather than cvclohexylisocvanate. the product (compound 71) is obtained as a solid. mp 228-230°C (dec).
MS (APCD) M~1: Calcd 443: Found 445.
EXAMPLE 128 7-Amino-2-methylsulfanyl-pyridof2,3-djpyrimidine-6-carboxylic acid ethyl ester
To a solution of 4-amino-2-methanesulfanyl-pyrimidine-5-carboxaldehyde (Example 3) in 10 mL of tetrahydrofuran is added 0.126 mL (1.18 mmol) of ethyl cvanoacetate. The solution is cooled to -10°C. and treated with 2.36 mL (2.36 mmol) of titanium tetrachloride. To the solution is slowly added 0.52 mL (4.72 mmol) of N-methyl morpholine. The reaction is warmed to room temperature over 2 hours. and partitioned between ethyl acetate and saturated aqueous ammonium chloride. The organic layer is concentrated to give a solid. which is triturated with ether to give 0.30 g (96%) of the product as a solid.
MS (APCI) M=+1: Caled 265.1: Found 264.9.
EXAMPLE 129 7-Amino-2-chloro-pyrido[2.3-dJpyrimidine-6-carboxylic acid ethyl ester
To a suspension of the product of Example 128 in 50 mL of chloroform is slowly added sulfuryl chloride. followed by 2 drops of ethanol. The reaction is stirred at room temperature for 16 hours. poured into ether. and the solid collected to give 0.50 g (98%) of the product.
MS (APCI) M+1: Caled 253.1: Found 253.1.
EXAMPLE 130 7-Amino-2-[4-(4-tert-butoxycarbonyl-piperazin-1-yl)-phenylamino/-pyrido[2,3- dJpyrimidine-6-carboxylic acid ethyl ester
A solution of the product of Example 12 and the product of Example 129 in dioxane is heated under reflux for 1.3 hours. The reaction is poured into hexane/ethyl acetate (1:1). and the solid is collected. Flash chromatography using . dichloromethane as eluant gave 0.08 g (16%) of the product as a solid.
MS (APCI) M+1: Caled 494.2: Found 494.1.
EXAMPLE 131 3 2-[4-(4-tert-Butoxycarbonyl-p iperazin-1-yl)-phenylamino]-7-(3-tert-butyi- ureido)-pyridof2,3-d[pyrimidine-6-carboxylic acid ethyl ester
By substituting the product of Example 130 in Example 10. 0.05 g (48%) of the product as a solid is obtained.
EXAMPLE 132 7-(3-tert-Butyl-ureido)-2-(4-piperazin-1 -vl-phenylamino)-pyrido[2,3- d]pyrimidine-6-carboxylic acid ethyl ester
By substituting the product of Example 131 in Example 15. 0.036 g of the product (compound 113) as a solid is obtained. mp >300°C.
EXAMPLE 135 13 1-[6-Fluoro-5-methyl-2-(4-piperazin-1 -yl-phenylamino)-pyrido[2,3-d[pyrimidin- 7-yl}-3-isopropyl-urea
Using the general procedure by which Example 52 is synthesized. but using 1-(4-amino-2-methylsulfanyi-pyrimidin-3-yi)-ethanone (Example 35). 4-(4- amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (Example 12). and isopropyl isocyanate as reagents. the product (compound 114) is obtained as a solid. mp 208°C (dec).
MS (APCI) M+1: Calcd 439.2: Found 439.5.
EXAMPLE 154 ‘ 1-Cyclohexyl-3-{2-[4-(3.3 -dimethyi-piperazin-1-yl)-phenvlamino/-pyridof2,3- 23 d[pyrimidin-7-yl}-urea
Using the general procedure by which Example 17 1s svnthesized. but using 4-(4-amino-phenv1)-2.2-dimethyl-piperazine-1-carboxylic acid tert-butyl ester (Example 96). 0.95 ¢ (100%) of the product (compound 115) 1s obtained as a solid.
MS (APCI) M~+1: Caled 475.6: Found 475.3. } Anal. Caled for CogH34NgO}-3 HCI-1 HaO:
C. 51.96: H. 6.37: N. 18.64: CL. 17.69: H»0. 2.99.
Found: C. 52.00: H. 6.41: N. 18.53: CL. 16.51: H2O. 3.06. 3 EXAMPLE 155 6-Methyl-2-methyisulfanyl-pyrido[2,3 -d|pyrimidin-7-ylamine
To a suspension of 2.18 g (34 mmol) of 60% oil dispersed sodium hydride in 300 mL of tetrahydrofuran. cooled to 10°C. is added 10.2 g (53.4 mmol) of (1-cyano-1-methyl-methyl)-phosphonic acid diethyl ester (Svnrhesis. 1975:516).
To the cooled suspension is added 4.30 g (25.4 mmol) of 4-amino-2- methanesulfanyl-pyrimidine-3-carboxaldehyde (Example 3). and the reaction is stirred at room temperature for 22 hours. The resulting solution is concentrated and filtered to give a solid. which is washed with tetrahvdrofuran. dissolved in
IN citric acid. and re-precipitated by adjusting the pH to 8 with 50% sodium hydroxide. The solid is collected by filtration to give 1.1 g (21%) of the product. mp 268-270°C.
MS (APCI) M+1: Caled 207.3: Found 207.0.
EXAMPLE 136
I-Cyclohexyl-3-{2-[4-(cis-3, 5-dimethyl-piperazin-1-yl)-phenylaminof-6-methyi- pyrido[2,3-d[pyrimidin-7-ylj-urea
Using the general procedure by which Example 31 is synthesized. but using the product of Example 135 as the starting material. 0.14 g (42%) of the product (compound 116) is obtained as a solid.
MS (APCI) M~+1: Calcd 589.6: Found 589.5. . 25 Anal. Caled for C17H36Ng01-2.5 HCI 1.5 Ha O:
C.53.80: H. 6.73: N. 18.01: Cl. 14.11: HO. 4.06.
Found: C.353.44: H. 6.89: N. 18.46: CL. 14.60: H>O. 4.48.
EXAMPLE 157 1 —tert-Butyl-3-{2-[4-(cis-3,5-dimetityl-piperazin-1-yl)-phenylamino]-6-methyl- pyrido[2,3-d[pyrimidin-7-yl}-urea . Using the general procedure by which Example 29 is synthesized. but using the product of Example 135 as the starting material, 0.26 g (89%) of the product (compound 117) is obtained as a solid.
MS (APCI) M~1: Calcd 463.6: Found 465.5.
Anal. Caled for CnsH3NgO1-2.4 HCI-1.75 H2O:
C. 51.62: H. 6.91; N. 19.26: Cl. 14.63: HyO. 5.42. ‘Found: C.51.23: H. 6.35: N. 18.92: Cl. 14.73: H70. 5.10.
EXAMPLE 138
I-tert-Butvi-3-[6-methyl-2-(4-piperazin-1-yl) -phenylamino)-pyridof2,3- dpyrimidin-7-yl[-urea
Using the general procedure by which Example 15 is synthesized. but using the product of Example 135 as the starting material. 1.02 g (100%) of the product (compound 118) is obtained as a solid.
MS (APCI) M+1: Calcd 435.3: Found 435.3.
Anal. Calcd for Co3H30NgO1-5 HCI-1.75 Ho 0:
C. 42.60: H. 3.98: N. 17.28: C1. 27.34: H»O. 4.86.
Found: C.42.03:H. 6.04: N. 16.81: C1. 22.95: Hy0. 4.72.
EXAMPLE 159 1-{2-[4-(cis-3,5-Dimethyl-piperazin-1-yl)-ph envlaminof-6-methyl-pyrido[2,3- d]pyrimidin-7-yl}-3-isopropyl-urea
Using the general procedure by which Example 33 is synthesized, but ‘ 25 using the product of Example 135 as the starting material. along with 4-(4-amino- phenyl)-cis-2.6-dimethyl-piperazine-] -carboxylic acid tert-butyl ester and isopropylamine as reagents. 0.130 g (100%) of the product (compound 119) is obtained as a solid.
MS (APCI) M~1: Calcd 449.3: Found 449 3.
Anal. Caled for C4H37Ng01-3 HCI-1.75 HaO: - C. 48.90: H, 6.58: N. 16.01: Cl. 16.04; H»O. 5.35.
Found: C. 49.03: H, 6.63; N. 18.70: Cl. 16.03; HO. 5.19.
EXAMPLE 140 1-Cvclopropyl-3-{2-[4-(cis-3 .5-dimethyi-piperazin-1-yl)-phenylamino]-6-methyl- pyrido[2.3-d]pyrimidin-7-ylj-urea
Using the general procedure by which Example 33 is synthesized. but using the product of Example 135 as the starting material. along with 4-(4-amino- phenyl)-cis-2.6-dimethyl-piperazine-1-carboxylic acid tert-butyl ester and cvclopropylamine as reagents, 0.099 g (100%) of the product (compound 120) is obtained as a solid.
MS (APCI) M+1: Calcd 447.3: Found 447.3.
Anal. Caled for C24H30NgO1:
C. 49.83: H. 6.19: N. 19.37; Cl. 18.39: HO. 3.89.
Found: C. 49.76: H. 6.23; N. 18.92: Cl. 15.66; HO. 3.06.
EXAMPLE 141 1-tert-Butyl-3-{2-[4-(cis-3 ,5-dimethyl-piperazin-1-yl)-phenylamino|-6-ethyl- pyrido[2,3-d[pyrimidin-7-yl}-urea
Using the general procedure by which Example 137 is synthesized, but using (1-cyano-propyl)-phosphonic acid diethyl ester as starting material. 0.34 g (95%) of the product (compound 121) is obtained as a solid.
MS (APCI) M+1: Calcd 477.3: Found 477.3.
Anal. Calcd for CogHogNgO1-2.5 HCI] H-O:
C. 53.26: H. 7.05: N. 19.11: CL. 15.18: Hy0. 3.07.
Found: C. 53.63: H. 7.31: N. 18.46: CL. 13.32: HO. 3.48.
EXAMPLE 142
The following compounds are prepared essentially according to the procedures described in Examples 1-141 and shown in Schemes 1-4:
(a) 1-tert-Butyl-3-[2-(3-chloro-4-piperazin-1 -vi-phenylamino)- pyrido[2.3-d]pyrimidin-7-yl]-urea (compound 2): (b) 1-tert-Butyl-3-[6-fluoro-2-(4-piperazin-1-yl-phenylamino)- ‘ pvrido[2.3-d]pyrimidin-7-yl]- urea (compound 3): (c) 1-{2-[4-(4-Acetyl-piperazin-1 -y1)-3-chloro-phenylamino]- pyrido{2.3-d]pyrimidin-7-v1] -3-tert-butvl-urea (compound 6): (d) 1-{2-[4-(4-Acetyi-piperazin-1-ylj-phenylaminoj-6-fluoro- pyrido[2.3-d]pyrimidin-7-y1} -3-tert-butyvl-urea (compound 7): (e) 1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino}-3-methyi- pyrido[2.3-d]pyrimidin-7-yl }-3-tert-butyl-urea (compound 8): (f) 1-[2-(3-Chloro-4-piperazin-1 -vl-phenylamino)- pvrido[2.3-d]pyrimidin-7-y1}-3-cyclohexyl-urea (compound 10). (g) 1-{2-[4-(4-Acetyl-piperazin-1-yl )-phenvlamino]- pvrido[2.3-d]pyrimidin-7-y1}-3-cyclohexyl-urea (compound 13): 135 (h) 1-{2-[4-(4-Acetyl-piperazin-] -v1)-3-chloro-phenylamino]- pyvrido[2.3-d]pyrimidin-7-y1}-3-cvclohexyl-urea (compound 14): (1) 1-{2-[4-(4-Acetyl-piperazin-1 -v1)-phenylamino]-6-fluoro- pyrido[2.3-d]pyrimidin-7-yv1} -3-cvclohexyl-urea (compound 15): €)) 1-{2-[4-(4-Acetyl-piperazin-1-vl )-phenylamino}-3-methyl- pvrido[2.3-d]pyrimidin-7-y1}-3-cyclohexyl-urea (compound 16): (k) 1-(2-Hvdroxy-ethyl)-3-[2-(4-piperazin-1-yl-phenviamino)- pyrido[2.3-d]pyrimidin-7-yl}-urea (compound 17): 1) 1-[2-(3-Chloro-4-piperazin-1 -vl-phenylamino)- pyrido[2.3-d]jpyrimidin-7-yl}-3-(2-hydroxy-ethyl)-urea (compound 18): 23 (m) 1 -[6-Fluoro-2-(4-piperazin- 1-v1)-phenylamino)- pvrido[2.3-d]pyrimidin-7-y1]-3-(2-hydroxy-ethyl)-urea (compound 19): (n) 1-(2-Hvdroxy-ethyl)-3-[ 5-methyl-2-(4-piperazin-1 -vl- phenylamino)-pyrido[2.3-d]pyrimidin-7-yl]-urea (compound 20): } (0) 1-12-[4-(4-Acetyl-piperazin-1-yl )-phenylamino]- pyrido[2.3-d}pyrimidin-7-y1} -3-(2-hvdroxy-ethyl)-urea (compound 21): (p) 1-12-[4-(4-Acetyl-piperazin-1-yl )-3-chloro-phenylamino}- pvrido[2.3-d]pyrimidin-7-yl }-3-(2-hvdroxy-ethyl)-urea (compound 22):
(Q) 1-{2-[4-(4-Acetyl-piperazin-] -vl)-phenvlamino]-6-fluoro- pvrido[2.3-d]pyrimidin-7-y1 }-3-(2-hvdroxy-ethyl)-urea (compound 23): (n) 1-{2-[4-(4-Acetyl-piperazin-1 -yl)-phenylamino]-3-methyl- . pyrido[2.3-d]pyrimidin-7-¥1}-3-(2-hydroxy-ethyl)-urea (compound 24): (s) 1-Ethyl-3-[2-(4-piperazin-1-yl-phenvlamino)- pyridof2.3-d]pyrimidin-7-y1]-urea (compound 25): (1) 1-[2-(3-Chloro-4-piperazin-1-yvl-phenylamino}- pyvrido[2.3-d}pyrimidin-7-y1}-3-ethyl-urea (compound 26): (u) 1-Ethyl-3-[6-fluoro-2-(4-piperazin-1-yl-phenylamino)- pyrido[2.3-d]pyrimidin-7-yl]-urea (compound 27): (v) 1-1{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]- pyrido[2.3-d}pyrimidin-7-v1}-3-ethyl-urea (compound 29). (w) 1-{2-[4-(4-Acetyl-piperazin-1-y])-3-chloro-phenylaminoj- pvrido[2.3-d]pyrimidin-7-y1}-3-ethyl-urea (compound 30): 13 (x) 1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-6-fluoro- pyvrido[2.3-d]pyrimidin-7-y1;-3-ethyl-urea (compound 31): (v) 1-{2-[4-(4-Acetyl-piperazin-1-y])-phenylamino]-3-methyl- pvrido{2.3-d]pyrimidin-7-y1}-3-ethyl-urea (compound 32): (2) 1-tert-Butvl-3-[2-(pyridin-4-ylamino)-pyrido[2.3-d pyrimidin- 7-vl]-urea (compound 33): (aa) 1 -Cvclohexyvi-3-[2-(pytidin-4-vlamino)-pyrido[2.3-d]pyrimidin- 7-vl]-urea (compound 34): (bb) 1-Ethv]-3-[2-(pyridin-4-ylamino)-pyrido[2.3-d]pyrimidin- 7-vl]-urea (compound 35): 23 (cc) 1-(Hvdroxy-ethyl)-3-[2-(pyridin-4-ylamino)- pvrido[2.3-d}pyrimidin-7-yl}-urea (compound 36): (dd) 1-tert-Butx 1-3-[6-fluoro-2-(pyridin-4-ylamino)- ’ pyvrido[2.3-d}pyrimidin-7- v1]-urea (compound 37): (ee) 1-Cvclohexyl-3-[6-fluoro-2-(pyridin-4-ylamino)- pyrido[2.3-d]pyrimidin-7-vl]-urea (compound 38): (fH) 1-Ethyl1-3-{6-fluoro-2-(pyridin-4-viamino)- pyrido[2.3-d]pyrimidin-7-11]- urea (compound 39):
(gg) 1-[6-Fluoro-2-(pyridin-4-ylamino)-pyrido[2.3-d]pyrimidin-7-y1}- ] 3-(2-hydroxy-ethyl)-urea (compound 40); (hh) 1-tert-Butyl-3-[5-methyl-2-(pyridin-4-ylamino)- : pyrido[2.3-d]pyrimidin-7- yl]-urea (compound 41): (i1) 1-Cyclohexyl-3-[3-methyl-2-(pyridin-4-ylamino)- pyvrido[2.3-d]pyrimidin-7-yl]-urea (compound 42): aj) 1-Ethvl-3-[5-methyl-2-(pyridin-+-yiamino)- pyvrido[2.3-d]pyrimidin-7-vi]- urea (compound 43): (kk) 1 -(2-Hydroxy-ethyl)-3-[5-methyl-2-(pyridin-4-ylamino)- pyrido[2.3-d]pyrimidin-7-yl]-urea (compound 44): (Ih 1 -Cyclohexyl-3-[6-methyl-2-(4-piperazin- 1-vl-phenylamino)- pyrido [2.3-d]pyrimidin-7-yl]-urea (compound 34); (mm) 1 -Cyclohexyl-3-[6-cyano-2-(4-piperazin-1 -yl-phenylamino)-pyrido [2.3-d]pyrimidin-7-yl]-urea (compound 56): (nn) 1-Cyclohexyl-3-[6-chloro-2-(4-piperazin-1 -yl-phenylamino)- pyrido [2.3-d]pyrimidin-7-yl}-urea (compound 57): (00) 1-Cyclohexyl-3-[6-fluoro-3-methyl-2-(4-piperazin-1-yl- phenylamino)-pyrido{2.3-d]pyrimidin-7-yl}-urea (compound 58); (pp) |! -Cyclohexyl-3-[6-bromo-5-methyl1-2-(4-piperazin-1 -vl- phenvlamino)-pyrido[2.3-d]pyrimidin-7-yl}-urea (compound 59): (qq) 1-Cyclohexyl-3- [6-chloro-3-methyl-2-(4-piperazin-1-yl- phenylamino)-pyrido[2.3-d])pyrimidin-7-yl]-urea (compound 60): (1) 1-Isopropyl-3-[5-methyl-2-(4-piperazin-1 -vl-phenylamino)- pvrido[2.3-d]pyrimidin-7-yl]-urea (compound 61): (ss) 1-[5-Methyl-2-(4-piperazin-1-yl-phenylamino)- pvrido[2.3-d]pyrimidin-7-yv1}-urea (compound 63): (tt) 1-(4-Hvdroxy-cyclohexyl)-3-[2-(4-piperazin-1 -vl-phenylamino)- pyrido [2.3-d]pyrimidin-7-vl]-urea (compound 66): (uu) 1-(4-Amino-cvclohexyl)-3-[2-(4-piperazin-1-yl-phenylamino)- pyrido [2.3-d}pyrimidin-7-yl]-urea (compound 67): (vv) 1 -(2-Dimethvlamino-ethyl)-3-[2-(4-piperazin-1-yl-phenylamino)- pvrido [2.3-d]pyrimidin-7-yl]-urea (compound 68):
(ww) 1-(3-Morpholino-4-yl-propyl)-3-[2-(4-piperazin-1-vl- phenylamino)-pyrido [2.3-d]pyrimidin-7-yl]-urea (compound 69): (xx) 1-Cyclohexyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)- . pvrido [2.3-d]pyrimidin-7-yl}-thiourea (compound 72): (vy) N-[2-(4-Piperazin-1-yl-phenylamino)-pyrido[2.5-d]pyrimidin- 7-v]]-acetamide (compound 73): (zz) 4-[7-(3-Cyclohexyl-ureido)-pyrido[2.3-d]pyrimidin-2-viamino}- benzenesulfonamide (compound 74): (aaa) 1-Cyclohexyl-3-{2-{4-(1-piperazin-i-yl-methanoyl)-phenylamino}- pyrido[2,3-d]pyrimidin-7-yl}-urea (compound 75): (bbb) 1-Cyclohexyl-3-[2-(4-fluoro-phenylamino)- pyrido[2.3-d]pyrimidin-7-yl}-urea (compound 76): (cee) 1-(2-{4-[4-(2-Amino-4-methyl-pentanoyl)-piperazin-1-yI]- phenylamino}-pyrido[2.3-d]pyrimidin-7-yl)-3-cyclohexyl-urea (compound 77): and (ddd) 1-(2-{4-[4-(2-Amino-3-methyl-butanoyl)-piperazin-1-yl}- phenylamino}-pyrido[2.3-d]pyrimidin-7-yl)-3-cyclohexyl-urea (compound 78).
EXAMPLE 143
Biological Assay
As noted above. the compounds of this invention are potent inhibitors of cdks. and accordingly. are useful in treating and preventing atherosclerosis and other cell proliferative disorders like cancer that are mediated by such cdk enzymes. The compounds exhibit excellent inhibitory activity against a number of cdk enzymes. including cdkcdk/cyclinB. cdk2/cyclinA. cdk2/cyvclinE, and cdk4/cvclinD. when evaluated in standard assays routinely utilized by those skilled in the art to measure cdk inhibitory activities. Typical assays are carried ’ out as follows.
Cyclin Dependent Kinase 4 (cdk4) Assay
Enzyme assays for IC 5( determinations and kinetic evaluation are performed in 96-well filter plates (Millipore MADVN6550). The total volume is 0.1 mL containing a final concentration of 20 mM TRIS
(tris[hvdroxymethyl]aminomethane). at pH 7.4. 50 mM NaCl. 1 mM dithiothreitol. 10 mM MgCla. 25 uM ATP containing 0.25 uCi of [32PJATP. 20 ng of cdk4. 1 pg of retinoblastoma. and appropriate dilutions of a compound of the ’ present invention. All components except the ATP are added to the wells. and the plate is placed on a plate mixer for 2 minutes. The reaction is started by adding [32P]ATP. and the plate is incubated at 25°C for 15 minutes. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid (TCA). The plate is kept at 4°C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% TCA and 32P incorporation is determined with a beta plate counter (Wallac Inc.. Gaithersburg. MD).
Cyclin Dependent Kinase 1 and 2 Assays ( cdk1/cyclinB, cdk2/cyclinA, cdk2/cyclinE)
Enzyme assavs for ICs determinations and kinetic evaluation are performed in a 96-well filter plate (Millipore MADVN6550) in a total volume of 0.1 mL of 20 mM TRIS (tris[hvdroxymethyl]aminomethane), at pH 7.4. 50 mM
NaCl. 1 mM dithiothreitol. 10 mM MgCls. 12 mM ATP containing 0.25 pCi of [32P]ATP. 20 ng of enzyme (either cdk1/B. cdk2/A. or cdk2E). 1 pg retinoblastoma. and appropriate dilutions of the particular invention compound.
All components except the ATP are added to the wells. and the plate 1s placed on a plate mixer for 2 minutes. The reaction is begun by addition of [32P]ATP. and the plate is incubated at 25°C for 15 minutes. The reaction 1s terminated by addition of 0.1 mL of 20% TCA. The plate is kept at 4°C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 3 times with 0.2 mL of 10%
TCA and 32P incorporation determined with a beta plate counter (Wallac Inc,
Gaithersburg. MD). . Cyclin Dependent Kinase 5/p25 Proline-directed Protein Kinase Assay
Source of enzyme: recombinant baculovirus-infected insect cell sf9-expressed recombinant cdk3-p23 complex.
Purpose: To evaluate the ability of test agents to inhibit cdk5/p25 phosphorylation of Histone HI.
Method: Baculovirus-insect cell His-tagged cdk5/Glu-tagged p25 (or . GST-p235) enzyme complex is diluted to a concentration of 50 ng/20 pL in b) Enzyme Dilution Buffer (EDB - 50 mM Tris-HCI [pH 8.0]. 10 mM NaCl. 10 mM
MgCly.and | mM DTT). AZ20 iL sample of test agent (diluted in EDB) is then combined with 20 uL of the of the final cdk3/p25 enzyme preparation and allowed to stand for 3 minutes at room temperature. Twenty-five microliters of substrate solution containing 115 pL/mL Histone H1. 30 uM ATP (vanadate-free). and 30 pCi/mL y-33P ATP (Amersham) in EDB is then added to the test agent/enzyme preparation and shaken at 30°C for 45 minutes. A 50 ul sample of the final preparation is added to 100 mL of 150 mM phosphoric acid on ice for 30 minutes to facilitate precipitation. The precipitate is then filtered through a 96-well phosphocellulose filter plate and subsequently rinsed 3 times with 75 mM phosphoric acid. Each well then receives 20 pL of scintillation cocktail. and the plates are counted for beta emissions using a Trilux Counter (33P filter protocol).
Test samples are compared to Control (no test agent present: as 0% inhibition) and
Baseline level (no enzyme. no test agent: as 100% inhibition) beta emissions to determine the percent inhibition of Histone H1 phosphorylation.
The results of the foregoing assays for representative invention compounds are presented in Table 2 below. The invention compounds exhibit IC5( values ranging from 0.027 uM to >35 uM against cdk1/B. from 0.010 uM to >5 uM against cdk2/A. from 0.020 to >5 uM against cdk2/E. and from 0.004 to >5 uM against cdk4/D. The most potent compound overall is compound 9. which exhibits IC3q values of 0.027 uM. 0.010 pM. 0.020 uM. 0.005 pM. against cdk1/B. cdk2A. cdk2E. and cdk4D. respectively.
TABLE 2. Inhibition of Cdks: IC50 (uM)
Compound Cdkl/B__ CdkZ/A Cdk2E CdkdD —71 0219 0060 0.130 0.006 4 >5 >5 >3 1.5 3 0.465 0.150 0.130 0.057 9 0.027 0.010 0.020 0.003 11 0.159 0.092 0.125 0.011 12 >5 >35 >5 2.100 28 >35 >3 >3 >3 45 0.552 0.054 0.110 0.045 46 0.073 0.300 >3 47 >5 >3 >35 >5 48 0.257 0.113 0.098 0.018 49 0.911 0.528 0.475 0.050 50 0.069 0.022 0.035 0.007 51 0.053 0.024 0.030 0.004 52 0.472 0.215 0.126 0.027 55 >5 >3 >3 >3 -
TABLE 2. Inhibition of Cdks: IC5¢0 (uM) (cont)
Compound Cdk1/B__ Cdk2/A Cdk2E Cdk4D ——s5 ____>5 _ >5 _ >5 0300 64 >3 >5 >5 >5 65 ~3 >3 >5 >5 70 1.448 0.697 0.530 0.017 71 >5 >5 >5 >5 79 >5 1.066 >5 >5 80 0.461 0.092 0.230 0.460 81 2.610 1.560 3.250 0.500 85 0.399 0.305 0.315 0.055 84 >5 >3 >5 >5 85 >3 >3 >5 >5 86 >3 >5 >5 >3 87 >3 >3 >5 >3 88 0.418 0.043 0.053 0.025 89 >3 >5 >5 >3 91 >3 >5 >5 0.070 93 >3 >3 >3 >5 94 >5 0.101 93 >3 0.310 . 96 6.363 1.108 1.530 >35 97 0.862 0.278 0.345 >3
SE —
TABLE 2. Inhibition of Cdks: IC5q (uM) (cont)
Compound Cdkl/B Cdk2/A Cdk2/E CdkdD — 98 0442 0.157 0140 1.050 99 1.810 1.012 0.410 >3 100 0.265 0.133 0.415 0.035 102 3.130 3.590 4.500 0.165 103 >5 >> >5 >3 104 >3 >3 >35 0.185 106 0.350 0.440 107 1.728 1.950 1.650 0.019 108 2.425 2.035 3.050 0.067 111 >5 >5 >3 >3 113 >5 >5 >5 5.000 114 >3 >5 >3 >5 115 0.054 0.022 0.051 0.007 116 >3 >35 3.750 0.313 117 >5 >5 4.000 0.076 118 >3 >5 3.800 0.079 119 >3 >3 >3 1.600 120 >3 >3 >5 1.900 ’ 121 >3 >5 >3 0.092
The compounds of this invention also are inhibitors of the growth factor receptor tyrosine kinase enzymes. FGFr and PDGFr. and of the nonreceptor wrosine kinase enzyme. c-Src. Several of the invention compounds have been evaluated via standard assays that measure their ability to inhibit tyrosine kinase enzymes. These assays are carried out as follows:
PDGF and FGF Receptor Tyrosine Kinase Assays
Full-length cDNAs for the mouse PDGF- and human FGF-1 (fle) receptor tyrosine kinases are obtained from J Escobedo and prepared as described inJ Biol Chen..1991:262:1482-1487. PCR primers are designed tc amplify a frasment of DNA that codes for the intracellular tvrosine kinase domain. The fragment 1s inserted into a baculovirus vector. cotransfected with AcCMNPV DNA. and the recombinant virus isolated. SF9 insect cells are infected with the virus to overexpress the protein. and the cell lysate 1s used for the assay. Assays are performed in 96-well plates (100 pL/incubation/well). and conditions are optimized to measure the incorporation of 32P from v32P-ATP into a glutamate- tyrosine co-polymer substrate. Briefly. to each well is added 82.5 pL of incubation buffer containing 25 mM Hepes (pH 7.0). 150 mM NaCl. 0.1% Triton X-100. 13 0.2 mM PMSF. 0.2 mM Na3VOy4. 10 mM MnCl». and 750 pg/mL of Poly (4:1) glutamate-tyrosine followed by 2.5 uL of inhibitor and 5 pL of enzyme lysate (7.5 pg/uL FGF-TK or 6.0 ug/ul PDGF-TK) to initiate the reaction. Following a 10-minute incubation at 25°C. 10 mL of y32P-ATP (0.4 uCi plus 50 uM ATP) is added to each well. and samples are incubated for an additional 10 minutes at 75°C. The reaction is terminated by the addition of 100 pL of 30% trichloroacetic acid (TCA) containing 20 mM sodium pyrophosphate and precipitation of material onto glass fiber mats (Wallac). Filters are washed 3 times with 15% TCA containing 100 mM sodium pyrophosphate. and the radioactivity retained on the filters counted in a Wallac 1250 Betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples with buffer : alone (no enzyme). Specific enzymatic activity (enzyme plus buffer) is defined as total activity minus nonspecific activity. The %o inhibition at 50 uM is determined. and for the more potent compounds the concentration of the compound that inhibited specific activity by 50% (IC5() is determined based on the inhibition curve.
C-Src kinase Assay
C-Src kinase is purified from baculovirus infected insect cell lysates using an antipeptide monoclonal antibody directed against the N-terminal amino acids (amino acids 2-17) of c-Src. The antibody. covalently linked to 0.65 um latex beads. is added to a suspension of insect cell lysis buffer comprised of 150 mM
NaCl. 50 mM Tris pH 7.5. 1 mM DTT. 1% NP-40. 2 mM EGTA. 1 mM sodium vanadate. 1 mM PMSF. 1 pgsmL each of leupeptin. pepstatin. and aprotinin. Insect cell lvsate containing c-Src protein is incubated with these beads for 3 to 4 hours at 4°C with rotation. At the end of the lysate incubation. the beads are nnsed 3 times in lysis buffer. resuspended in lysis buffer containing 10% glycerol. and frozen. These latex beads are thawed. rinsed 3 times in assay buffer (40 mM Tris. pH 7.5. 5 mM MgCl»). and suspended in the same buffer. In a Millipore 96-well plate with a 0.65 um polyvinylidine membrane bottom are added the reaction components: 10 pL c-Src beads. 10 uL of 2.5 mg/mL poly GluTyr substrate. 5 pM
ATP containing 0.2 uCi labeled 32p_ATP. 5 uL DMSO containing inhibitors or as a solvent control. and buffer to make the final volume 125 pL. The reaction is started at room temperature by addition of the ATP and quenched 10 minutes later by the addition of 125 pL of 30% TCA. 0.1 M sodium pyrophosphate for 5 minutes on ice. The plate is then filtered and the wells washed with two 250-mL aliquots of 15% TCA. 0.1 M pyrophosphate. The filters are then punched. counted in a liquid scintillation counter. and the data examined for inhibitory activity in comparison to a known inhibitor such as erbstatin. The method is also described in
J Med Chem., 1994:37:598-609.
The tyrosine kinase inhibitory acuvity for representative invention compounds evaluated in the foregoing assays is given in Table 3.
TABLE 3. Inhibition of Tyrosine Kinases: % Inhibition at 50 pM (IC5( [uM] in parenthesis if determined)
Compound PDGFr FGFr — 1 9440393) 9.7 9 89.8 11 (0.151) (0.284) 45 21.9 67.4 46 17.5 19.5 47 10.5 35 (0.053) (0.151) 70 (0.336) (1.15) 80 18.6 117 (0.081) (0.061)
As noted above. the invention also provides pharmaceutical compositions comprising an invention compound admixed with a carrier, diluent. or excipient.
The following examples illustrate typical compositions provided by this invention.
EXAMPLE 144 3 A pharmaceutical compositions in the form of hard gelatin capsules for oral administration is prepared using the following ingredients:
T Quantity (mgleapsule) “Active compound 250
Starch powder 200
Magnesium stearate 10
Tow 460 -
The above ingredients are mixed and filled into hard gelatin capsules in 460 mg quantities. A typical active ingredient is 1-isobutyl-3-[2-{(2-chloro-4- piperazin-1-yl)-phenylamino -pyrido[2.3-d}pyrimidin-7-yl}-urea. The composition is administered from 2 to 4 times a day for treatment of postsurgical restenosis. ]
EXAMPLE 144a ‘ Compositions for Oral Suspension
Tmeden Amount
Tisopropyl-3-[5-methyl-6-bromo-2-(-ethylpyridin-+- 500mg ylamino)-pyrido-[2.3-d]pyrimidin-7-y1j-urea
Sorbitol solution (70% NF) 40 mL
Sodium benzoate 130 mg
Saccharin 10 mg
Cherry flavor 50 mg
Distilled water g.s. ad 100 mL
The sorbitol solution is added to 40 mL of distilled water. and the pyridopyrimidine is suspended therein. The saccharin. sodium benzoate. and flavoring are added and dissolved. The volume is adjusted to 100 mL with distilled water. Each milliliter of syrup contains 5 mg of active ingredient.
EXAMPLE 144b
Tablets Each Containing 60 mg of Active Ingredient
Active mgrediemt __ 6img
Starch 43 mg
Microcrystalline cellulose dmg
Polvvinvipyrrolidone (as 10% solution in water) 4 mg
Sodium carboxymethyl starch 45mg
Magnesium stearate 0.5 mg
Talc 1.0 mg
The active ingredient. starch. and cellulose are passed through a No. 45 : mesh US sieve and mixed thoroughly. The solution of polvvinyvipyrrolidone is mixed with the resultant powders and then passed through a No. 14 mesh US sieve. The granules are dried at 50°C to 60°C and passed through a No. 18 mesh 'S sieve. The sodium carboxymethyl starch. magnesium stearate. and talc.
previously passed through a No. 60 mesh US sieve. are then added to the granules which. after mixing. are compressed on a tablet machine to vield tablets each weighing 150 mg.
A tvpical active ingredient utilized in the above preparation is the compound of Example 40 (Compound 12). This composition is well-suited to treatment of diabetic retinopathy.
EXAMPLE 144c¢
A parenteral composition suitable for administration by injection is prepared by dissolving 100 mg of compound 77 in 250 mL of 0.9% aqueous sodium chloride solution and adjusting the pH of the solution to about 7.0. This formulation is well-suited for the treatment of breast cancer.
EXAMPLE 144d
Preparation for Suppositories
A mixture of 500 mg of 1-n-butyl-3-[2-(4-piperazin-1-v]-phenylamino)- pyrido[2.3-d]pyrimidin-7-yl]-urea and 1500 mg of theobroma oil are blended to uniformity at 60°C. The mixture is cooled t0 24°C in tapered molds. Each suppository will weigh about 2 g and can be administered from 1 to 2 times each day for treatment of viral infections such as herpes and HIV.
EXAMPLE 144e
Topical Preparation
Tngrediem ________________ Amount(mg)
T-Cvclohexyl-3-{[2-(4-morpholin-1-yl-phenylamino)]-5.6- 20 difluoro-pyrido[2.3-d]pyrimidin-7-yl}-urea
Propylene glvcol 100
White Petrolatum 500
Cetearvl alcohol 50
Glvceryvl stearate 100
PEG 100 stearate 100
Ceteth-20 50
Monobasic sodium phosphate 80
Toul i000 -
The invention compound is blended to uniformity with the other ingredients to make a thick suspension. The suspension is applied evenly to an adhesive backed polvmeric film and cut into a 2-inch square. The patch 1s applied 3 to the skin of a patient suffering from psoriasis.
EXAMPLE 144f
Slow Release Preparation
Five hundred milligrams of 7-acetamido-6-bromo-2-[4-(2- diethylaminoethoxy)-phenylamino]pyrido{2.3-d]pyrimidine hvdrochloride was placed in an osmotic pump tablet and administered orally to a subject for treatment and prevention of restenosis.
The invention and the manner and process of making and using it are now . described in such full. clear. concise and exact terms as to enable any person skilled in the art to which it pertains to make and use the same. It 1s to be understood that the foregoing describes preferred embodiments of the present invention. and that modifications may be made therein without departing from the spirit or scope of the present invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as the invention. the following claims conclude this specification.

Claims (1)

CLAIMS What is claimed is:
1. A compound of the Formula I Rr ad R® Pp A AA _R’ EIN NE ME ! ! 3 and pharmaceutically acceptable salts. esters. amides. and prodrugs thereof. wherein:
R2.R7.RI3.RI+ and R13 are independently hydrogen. or jower alkyl. lower alkenyl. or lower alkynyl. each of which 1s optionally substituted with up to 5 groups independently selected from halogen. cvano. nitro. RY. -NRIRI10, -ORY, -(CHa),CORY. -(CH2),SORIL (CHa)pRIL -CORY, _CONRIR10. -SO3RY. -SO-NRIR10. -SO-R?. -SRY, -PO3RIR10, -PORIR10. -PONRIR10)5. -NRICORIO, NRICOHR!0. -NRICONRIR IO. -NRISO-R10. or 13 a heterocycle optionally substituted with up to 3 groups independently selected from -R9. -NRIR10. -OR, NRICOR10, .COR10. -(CH»),SO2RIL. «(CH2)R1L or -(CH»> )pR1= optionally substituted with up to 5 groups . 20 independently selected from halogen. cyano. nitro. -RY, ~NRIRI0. -ORY. (CH2), CORY. -(CH2)n SOR (CHa ),R!1.-CORY. -CONRIR10. -SO3R?.
ZA200205879A 2000-01-25 2002-07-23 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors. ZA200205879B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25

Publications (1)

Publication Number Publication Date
ZA200205879B true ZA200205879B (en) 2003-09-29

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200205879A ZA200205879B (en) 2000-01-25 2002-07-23 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors.

Country Status (34)

Country Link
EP (1) EP1254137A1 (en)
JP (1) JP4047010B2 (en)
KR (1) KR20020065939A (en)
CN (1) CN1395578A (en)
AP (1) AP2002002586A0 (en)
AR (1) AR030044A1 (en)
AU (1) AU2542501A (en)
BG (1) BG106850A (en)
BR (1) BR0107751A (en)
CA (1) CA2397961C (en)
CO (1) CO5261549A1 (en)
CR (1) CR6706A (en)
CZ (1) CZ20022475A3 (en)
DZ (1) DZ3266A1 (en)
EA (1) EA200200643A1 (en)
EE (1) EE200200405A (en)
GT (1) GT200100016A (en)
HN (1) HN2001000013A (en)
HU (1) HUP0204141A3 (en)
IL (1) IL150545A0 (en)
IS (1) IS6443A (en)
MA (1) MA26868A1 (en)
MX (1) MXPA02007221A (en)
NO (1) NO20023527L (en)
OA (1) OA12161A (en)
PA (1) PA8510701A1 (en)
PE (1) PE20011066A1 (en)
PL (1) PL356802A1 (en)
SK (1) SK10632002A3 (en)
SV (1) SV2002000294A (en)
TN (1) TNSN01014A1 (en)
WO (1) WO2001055147A1 (en)
YU (1) YU50402A (en)
ZA (1) ZA200205879B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AU2002246855B2 (en) 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
PE20030008A1 (en) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co DUAL INHIBITORS OF PDE 7 AND PDE 4
KR20040103972A (en) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 Novel Compounds
HRP20050601A2 (en) * 2002-11-28 2005-10-31 Schering Ag Chk-, pdk-, and akt-inhibitory pyrimidines, their production and use as pharmarmaceutical agents
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
EP1794160A1 (en) * 2004-09-21 2007-06-13 F.Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors
EP1865959A2 (en) 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
EP1868612A4 (en) 2005-03-25 2010-03-24 Glaxo Group Ltd Novel compounds
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
PE20061351A1 (en) 2005-03-25 2007-01-14 Glaxo Group Ltd 8H-PYRID [2,3-d] PYRIMIDIN-7-ONA 2,4,8-TRISUSTITUTED COMPOUNDS AS CSBP / RK / p38 KINASE INHIBITORS
FR2887882B1 (en) * 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
CN101243081A (en) * 2005-07-21 2008-08-13 霍夫曼-拉罗奇有限公司 Pyrido[2,3-d]pyrimidine-2,4-diamine compounds as PTP1B inhibitors
ATE482958T1 (en) 2005-08-09 2010-10-15 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (en) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co MAPK/ERK Kinase Inhibitors
FR2910813B1 (en) * 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP2352732B1 (en) * 2008-12-01 2013-02-20 Merck Patent GmbH 2,5-DIAMINO-SUBSTITUTED PYRIDO[4, 3-d]PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
US9815847B2 (en) 2013-03-14 2017-11-14 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (en) * 2014-09-02 2016-11-02 한국원자력의학원 Pyrimidine derivatives having anti-cancer effect, combination therapeutic effect with radiation, and anti-diabetic effect, and PPAR activity, and medical use thereof
CN107286180B (en) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 Heteropyridopyrimidinone derivatives as CDK inhibitors and their applications
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
ES2146782T3 (en) * 1994-11-14 2000-08-16 Warner Lambert Co 6-ARYL-PIRIDO (2,3-D) PIRIMIDINAS AND NAFTIRIDINAS FOR THE INHIBITION OF THE CELL PROLIFERATION INDUCED BY THE PROTEIN TIROSINA QUINASA.
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
DE69939168D1 (en) * 1998-05-26 2008-09-04 Warner Lambert Co BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELL REPRODUCTION

Also Published As

Publication number Publication date
PE20011066A1 (en) 2001-10-22
WO2001055147A1 (en) 2001-08-02
CN1395578A (en) 2003-02-05
EP1254137A1 (en) 2002-11-06
HUP0204141A2 (en) 2003-04-28
TNSN01014A1 (en) 2005-11-10
SV2002000294A (en) 2002-07-16
MXPA02007221A (en) 2002-11-29
EA200200643A1 (en) 2002-12-26
JP4047010B2 (en) 2008-02-13
CO5261549A1 (en) 2003-03-31
CR6706A (en) 2005-04-04
AR030044A1 (en) 2003-08-13
IS6443A (en) 2002-06-25
KR20020065939A (en) 2002-08-14
DZ3266A1 (en) 2001-08-02
HN2001000013A (en) 2001-06-18
NO20023527D0 (en) 2002-07-24
NO20023527L (en) 2002-09-10
PA8510701A1 (en) 2002-12-11
AP2002002586A0 (en) 2002-09-30
HUP0204141A3 (en) 2005-03-29
AU2542501A (en) 2001-08-07
BR0107751A (en) 2002-11-12
CZ20022475A3 (en) 2003-03-12
GT200100016A (en) 2001-10-19
EE200200405A (en) 2003-12-15
JP2003523357A (en) 2003-08-05
PL356802A1 (en) 2004-07-12
MA26868A1 (en) 2004-12-20
CA2397961A1 (en) 2001-08-02
YU50402A (en) 2005-11-28
CA2397961C (en) 2008-08-26
IL150545A0 (en) 2003-02-12
OA12161A (en) 2006-05-08
BG106850A (en) 2003-02-28
SK10632002A3 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
ZA200205879B (en) Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors.
US7053070B2 (en) Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
CA2329703C (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
AU777468B2 (en) Pteridinones as kinase inhibitors
JP6248123B2 (en) Substituted 1H-pyrrolo [2,3-b] pyridine and 1H-pyrazolo [3,4-b] pyridine derivatives as salt-inducible kinase 2 (SIK2) inhibitors
US20090312321A1 (en) Compositions and methods for fgf receptor kinases inhibitors
SK141097A3 (en) Pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US20040242600A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
US20040044012A1 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
NZ520962A (en) 5-alkylpyrido[2,3-d]pyrimidines cyclin-dependent tyrosine kinase inhibitors
AU2006302148A1 (en) Pyridopyrimidinone inhibitors of PI3Kalpha
US7323469B2 (en) 7H-pyrrolo[2,3-d]pyrimidine derivatives
OA11554A (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.
ZA200006536B (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.
MXPA00010738A (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
CZ20004246A3 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines functioning as inhibitors of cell proliferation